作者: nicole

TIME Interconnect Technology Limited Announces Final Results For The Year Ended 31 December 2024

HONG KONG, Apr 25, 2025 - (ACN Newswire via SeaPRwire.com) – TIME Interconnect Technology Limited (“TIME Interconnect”, Stock Code: 1729.HK, with its subsidiaries collectively referred to as the “Group”) , a leading manufacturer of cable assembly, digital cable, and server products, has recently announced its final results for the year ended 31 December 2024 is pleased to announce its final results for the year ended 31 December 2024 (the “Current Year” or “FY2024”). The Group achieved record-breaking growth, driven by strategic expansions in high-margin sectors and excellent execution. During the FY2024, global economic growth experienced a notable slowdown, primarily due to persistently high borrowing costs, the gradual withdrawal of fiscal support, and heightened geo-economic fragmentation. These factors collectively exerted downward pressure on overall market demand. Moreover, cyclical imbalances among major economies began to stabilise, with economic activities gradually returning to potential levels. Amid this challenging macroeconomic landscape, the Group demonstrated agility and resilience by accelerating its business transformation and product upgrades. Notably, it capitalised on the surging demand for server and data centre infrastructure driven by the rapid emergence of artificial intelligence (AI), which remained a key growth engine and contributed to strong revenue performance in the data centre and specialty cable segments. For the Current Year, the Group recorded revenue amounting to HK$7,388.8 million, represented an increase of HK$2562.5 million or 53.1% as compared with HK$4,826.3 million for the Previous Year. Operating profit for the Current Year was HK$623.6 million, represented an increase of HK$190.2 million or 43.9%, as compared with HK$433.4 million for the Previous Year. The operating profit margin dropped slightly from 9.0% to 8.4% for the Current Year, primarily attributable to an increase in research and development expenditure. Net profit of the Current Year was HK$450.5 million, represented an increase of HK$172.9 million or 62.3%, as compared with HK$277.6 million for the Previous Year, with the net profit margin raised from 5.8% to 6.1% for the Current Year*. Basic earnings per share for the Current Year was HK23.2 cents as compared to the basic earnings per share of HK14.2 cents in the Previous Year. Business Review The Group’s turnover by market sector is as follows: Market SectorTurnover (HK$ million) Share of Turnover Year ended 31 December 2024Nine months ended 31 December 2023ChangesYear ended 31 December 2024Nine months ended 31 December 2023Cable assembly Data centre1,213.5 791.0 53.4% 16.4% 16.4% Telecommunication566.8 555.4 2.1% 7.7% 11.5% Medical equipment 816.6 258.0 216.5% 11.1% 5.3% Industrial equipment 29.2 24.4 19.7% 0.4% 0.5% Automotive 157.7 100.4 57.1% 2.1% 2.1% Digital cable  Networking cable 1,179.9 788.7 49.6% 16.0% 16.4% Specialty cable 237.0 77.0 207.8% 3.2% 1.6% Server 3,188.1 2,231.4 42.9% 43.1% 46.2% Total 7,388.8 4,826.3 53.1% 100% 100% Data centre sectorThe revenue of the data centre segment increased by HK$422.5 million to HK$1,213.5 million for the Current Year as compared to HK$791.0 million for the Previous Year. Benefiting from the surge in artificial intelligence and server upgrades, shipment levels remained strong during the FY2024, and the sector remained to be the highest revenue contributor in the cable assembly business. Telecommunication sectorRevenue from the telecommunication sector rose by HK$11.4 million to HK$566.8 million for the Current Year, compared to HK$555.4 million in the Previous Year. Although part of the production capacity has been shifted to data centre sector due to its order volume increased. But better margin orders of telecommunication sector have been retained to improve the product portfolio of overall cable assembly business. Medical equipment sectorDuring the Current Year, the Group paid more attention and efforts in the medical equipment cables business and continued to enhance its medical equipment customers base, as well as to strengthen its R&D capabilities. Benefited from the setup of two new plants last year, Time Kunshan and Time Jiangxi, and expanded production capacity and R&D capabilities for medical equipment cables products, the revenue of the medical equipment sector for the Current Year significantly increased to HK$816.6 million, representing a substantial rise of HK$558.6 million compared to HK$258.0 million for the Previous Year. The Group continued to increase investment in this sector, enhancing both production capacity and R&D capabilities. The Group expects that, with growing health awareness, demand for medical equipment will continue to rise. Industrial equipment sectorDespite the underperforming global economic recovery, and the pressures from high inflation and interest rates on economic activities, the revenue of the industrial equipment sector increased. The revenue rose from HK$24.4 million in the Previous Year to HK$29.2 million for the FY2024, representing an increase of 19.7%. Automotive sectorDespite the ongoing impact of geopolitics and the trade war, sales orders for automotive wire harness products remained at a relatively low level. However, the revenue of the automotive sector increased to HK$157.7 million for the Current Year, up by HK$57.3 million from HK$100.4 million in the Previous Year.  The Group still believes that the automotive wiring products can help the Group to provide its customers with a broader product portfolio, and to step into a new business sector by enriching the Group’s business portfolio and broadening its unique customer base, which can capture opportunities brought by the booming electric vehicle market. Additionally, the Group established a wholly-owned subsidiary, Linkz Cables Mexico S. de R.L. de C.V. ("Linkz Mexico"), in Mexico, aiming to increase its market share outside China and Asia. Networking cable sectorEven a lot of negative factors, such as the divergences between countries, war, high interest rates, strong US dollar and high inflation, were remained exist, during the FY2024, overseas orders for the networking cable sector continued to improve, with revenue rising to HK$1,179.9 million, an increase of HK$391.2 million from HK$788.7 million in the Previous Year. The increase in copper prices reflects ongoing growth in market demand. Furthermore, the establishment of Linkz Mexico has helped enhance the Group's market share in the United States and Mexico. Specialty cable sectorDriven by the surge in demand for high-speed cables fuelled by artificial intelligence applications, the specialty cable sector experienced robust growth. Revenue for the sector increased significantly to HK$237.0 million for the FY2024, up by HK$160.0 million or 207.8% compared to HK$77.0 million in the Previous Year. The growth in high-speed cables also contributed to improved profit margins, further enhancing the Group's overall profitability. Server sectorDuring the Current Year, the revenue of the server sector grew significantly to HK$3,188.1 million, an increase of HK$956.7 million compared to HK$2,231.4 million in the Previous Year. Despite challenges in the first half of the year due to shortages in key component supplies, the Group worked very hard to find all the business solutions to cope with this situation. Finally, the supply of these key components has been resolved and the production has been resumed immediately, leading to a strong recovery in the second half. Continued strong demand for servers further drove business growth. ProspectDespite challenges in the macroeconomic environment, including global growth uncertainties and geopolitical tensions, the Group’s management remains confident in its future business development. Looking ahead, the Group will continue to embrace flexibility and continuous innovation, focusing on strengthening supply chain resilience, expanding international presence, and driving diversified business growth to ensure long-term development. In the FY2024, the Group has proactively expanded its overseas business with the establishment of Linkz Mexico, a wholly-owned subsidiary. The new factory is expected to commence full production within the year, primarily manufacturing digital cables and automotive wire harness products. This aligns with the "China-Plus-One" strategy, mitigating geopolitical risks and ensuring export stability. With the rapid growth in demand for electric vehicles, automotive wire harness products have become a key driver for the Group’s next phase of growth. Meanwhile, the acceleration of global 5G deployment, along with the normalisation of remote work and cloud applications, will continue to propel the Group’s growth in telecommunications cables and server solutions. In the server segment, the Group has successfully expanded its data centre product line through its JDM/ODM business model, continuously customising solutions to meet the needs of brand clients. Riding on the PRC government’s “channelling computing resources from the eastern areas to the western regions” initiative and leveraging Luxshare Group’s technological platform and market resources, the Group will further scale its data centre business and seize the significant market opportunities arising from the rapid advancement of artificial intelligence, big data, and cloud computing. In the medical technology sector, Dr. Cua Tin Yin Simon, the Group’s CEO, remains optimistic about the prospects, “In 2024, the Group further increased its investments, including a stake in a Japanese medical and healthcare company with a proven operational history of over 30 years. In addition, the Group invested in a UK-based startup with seven years of professional experience in haptics and virtual reality. This company has developed innovative wearable haptic technology capable of simulating weight, resistance, and assistive forces in virtual environments. With initial applications in digital health and fitness within the spatial computing space, the technology merges wellness, fitness, and gaming to optimise human performance—targeting the vast markets of gaming and neuromuscular rehabilitation. The Group believes that these strategic investments will allow it to leverage the companies’ technological expertise and create synergy in developing medical-related products, particularly in R&D, manufacturing, and global market expansion. In line with our expansion strategy, two new liaison offices—Time US and Time UK—have also been established to deepen our global business presence.” Additionally, in 2024, Dr. Cua facilitated the establishment of the Medical Engineering and Innovation Council under the Federation of Hong Kong Industries (FHKI), where he serves as Co-Chair alongside Chuang Tzu Hsiung, Chairman of both FHKI and the Hong Kong New Industrialisation Development Alliance. The council is dedicated to establish a medical engineering frontier tracking mechanism to deeply explore technology transformation and commercialization potential. Secondly, it constructs an integrated "Government-Industry-University-Research-Investment" collaborative platform, consolidating government policies, university R&D, clinical resources, and industrial capital. By establishing joint laboratories and rapid conversion channels, it accelerates the commercialization of scientific research outcomes. Simultaneously, the council strengthens cross-border cooperation by connecting global innovation networks, introducing international certification bodies and technology transfer platforms, assisting Hong Kong enterprises in overcoming overseas market access barriers, and establishing cross-border industry-university-research bases to reinforce the region's innovation hub status. Finally, it implements a full-cycle industry cultivation program, providing comprehensive support for start-ups from prototype development, regulatory certification, clinical trials to mass production. While promoting traditional industry transformation and global market expansion, it facilitates the formation of a complete ecosystem for Hong Kong's medical technology industry - "Research & Development - Conversion - Industrialization" - to address global health challenges and enhance international competitiveness. The Group believes that, while pursuing business growth, it is also essential to fulfill its corporate social responsibility by actively addressing social issues such as health, innovation, and industry upgrading. Moving forward, the Group will focus on high-potential areas, leveraging innovation, collaboration, and sustainability to strengthen its core competitiveness and position itself as a leading provider of network solutions and medical technology infrastructure, creating greater value for shareholders and society. Key Milestone - Establishment of the Medical Engineering and Innovation Council About TIME Interconnect Technology Limited TIME Interconnect Technology Limited is a well-established supplier of customised interconnect solutions with over 30 years’ experience in the industry. The Group is headquartered in Hong Kong, and has manufacturing facilities in Shanghai, Suzhou, Jiangxi and Huizhou, the People’s Republic of China (“PRC”), Japan and Mexico. The Group currently manufactures and supplies a wide variety of copper & optical fiber cable assemblies, digital cable products and servers which are produced to the specifications and designs of its individual customer partners. Its products are used by a number of established PRC and international customers in a variety of market sectors, including telecommunication, data centre, industrial equipment, medical equipment, automotive wire harness, digital cable and server. This press release is disseminated by Bright Communications International Limited on behalf of TIME Interconnect Technology Limited. For further enquiries, please contact Bright Communications International Limited: Ms. Ashley KungTel: (852) 46371627Mob: (852) 6608 9927Email:ashley.kung@brightcommns.com*Note: The financial year end date of the Company has been changed from 31 March to 31 December in July 2023. For details, please refer to the Company’s announcement dated 24 July 2023. In view of this change, the consolidated financial statements of the Group cover the twelve-month period from 1 January 2024 to 31 December 2024 and the comparative figures cover the nine-month period from 1 April 2023 to 31 December 2023. It should be noted that the financial data presented herein are being compared with that for the nine-month period ended 31 December 2023. The difference in duration of the two financial periods should be considered when making year-on-year comparisons. Copyright 2025 ACN Newswire via SeaPRwire.com.

26 4 月, 2025

Mooreast Holdings Announces Business Update

SINGAPORE, Apr 25, 2025 - (ACN Newswire via SeaPRwire.com) - The Board of Directors (“Board”) of Mooreast Holdings Ltd. (“Mooreast” or the “Company”), and together with its subsidiaries, the “Group”) wishes to provide an update on several recent developments: Completion of Multi-Buoy Mooring Upgrade Project at Gulf of ThailandFurther to the Company’s announcement dated 12 November 2024, Mooreast wishes to update that the project to upgrade a multi-buoy mooring (“MBM”) system off the eastern shore of the Gulf of Thailand was completed recently. The Group expects to recognise approximately S$8.8 million for this project in the first half of the financial year ending 31 December 2025 (“1H2025”).The successful completion underscores the Group’s capabilities to handle sizeable mooring projects within the oil and gas (“O&G”) industry. Orders related to the O&G sector had been building up in 2H2024, and have continued to gain momentum in the first four months of FY2025. Even with the delivery of the MBM project, current orders at hand are at least equal to those at the end of FY2024. Accordingly, the Group expects revenue in 1H2025 to exceed the S$13.7 million recorded in 1H2024.       Additionally, the Group does not expect that the administrative and other operating expenses to increase significantly in FY2025 given that the current staffing is sufficient to support operations and business development in the near term and the absence of fees for professional services rendered to support the Group’s business repositioning efforts in FY2024. Management is actively reviewing and implementing cost control measures to improve overall cost efficiency and profitability moving forward.Update on Floating Wind Energy Projects in Europe and North AsiaOn 1 January 2025, Mr. Eirik Ellingsen (“Mr. Ellingsen”), a Norwegian with deep experience in the offshore and marine sector, was appointed Chief Executive Officer (“CEO”). In the last four months, he has been working closely with Mr. Sim Koon Lam (“Mr Sim”), the founder, Executive Director and Deputy Chairman, on business development strategies amid an increase in commercialisation of floating wind energy projects worldwide.Mr. Ellingsen has been actively engaging players involved in floating wind energy projects in Europe and North Asia, and participated in the WindEurope conference in Copenhagen, Denmark, earlier this month. While the ‘first wave’ of implementation – involving largely demonstration and precommercial projects – had been delayed by the supply chain disruptions caused by the COVID-19 pandemic, the industry has clearly advanced to the ‘second wave’ – commercialisation at scale. With the progress toward commercialisation, the Environmental Resources Management’s “Q3 2024 Global Offshore Wind Market Update" reported over 390 GW of floating wind projects in various planning and development stages. Compared to 50-100 megawatts (“MW”) typical at pre-commercialisation, the latter involves projects of at least 500 MW each. Many of these projects are reaching the final investment decision (“FID”) phase in 2026 and 2027. These include multigigawatt (“GW”) scale projects which can contribute substantially to the growth of offshore wind capacity globally. Typically, mooring and rigging solutions, including anchors, chains, and ropes, account for between 5% to 10% of the total value of each floating wind energy project.           Approximately 5.5 GW of floating wind capacity is expected to reach FID in the next 24-36 months. Of this, about two-thirds involve projects in Europe, including those in the North Sea, while a third will come from North Asia. These projects may be deemed as the addressable market of Mooreast. As the Group is currently not targeting U.S. floating wind energy projects, it is not subject to U.S. Government tariffs for its products. Already, Mooreast is working closely with these projects and has indicated its component costings. As these progress to full implementation, developers and partners are looking for a reliable manufacturer capable of handling the large volumes of anchors and mooring components required for these large-scale projects. The Group believes it is uniquely positioned, given its status as Asia’s only ultra-high power anchor designer and manufacturer and its global footprint. Mooreast recently opened new offices in Taiwan and Malaysia in June and July 2024, respectively, expanding its presence in the Asian region.The Group continues to assess the ability of its present facility at 51 Shipyard Road in Singapore to handle production of anchors and components as these projects advance to formal tender, noting that developers have indicated suppliers would need to demonstrate beforehand sufficient capacity to handle the indicative volume. Should such orders escalate beyond the current capacity of the existing yard, Mooreast would need to explore access to additional capacity. Meanwhile, the Company continues to develop its supply chain to better serve its customers globally. The Company will provide updates to shareholders as and when there are material developments regarding floating renewable energy projects. BY ORDER OF THE BOARD MOOREAST HOLDINGS LTD.Mr Eirik Ellingsen Chief Executive Officer23 April 2025This announcement has been reviewed by the Company’s sponsor, UOB Kay Hian Private Limited (the “Sponsor”). This announcement has not been examined or approved by the Singapore Exchange Securities Trading Limited (“SGX-ST”) and the SGX-ST assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement.  The contact person for the Sponsor is Mr Lance Tan, Senior Vice President, 8 Anthony Road, #01-01, Singapore 229957, telephone (65) 6590 6881. Copyright 2025 ACN Newswire via SeaPRwire.com.

25 4 月, 2025

Coya Therapeutics Announces Positive Interim Results of an Investigator-Initiated Open Label Study with Low-Dose IL-2 and CTLA4-Ig Combination Treatment in Five Patients with Mild to Moderate Frontotemporal Dementia

- Results from the first patient cohort (N=5) of an open-label proof of concept academic study with low-dose IL-2 and CTLA4-Ig demonstrated a rapid and durable statistically significant increase in the number and suppressive function of Tregs compared to baseline values. - Clinically, patients with Frontotemporal Dementia (FTD) demonstrated minimal to no cognitive decline throughout the study period. Treatment was well tolerated, no serious adverse events were reported, and all 5 patients completed the study.Houston, TX, Apr 24, 2025 - (ACN Newswire via SeaPRwire.com) - Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function announced positive interim results of an investigator-initiated proof of concept open-label study with low-dose IL-2 and CTLA4-Ig combination treatment in patients with Frontotemporal Dementia (FTD). The study is led by Dr. Alireza Faridar and Dr. Stanley Appel at the Houston Methodist Neurological Institute (Houston, TX) with funding from The Peggy and Gary Edwards Endowment Fund. Study patients received subcutaneously administered CTLA4-Ig, followed by a 5-day course of low-dose IL-2 every four weeks, for a total of 22 weeks of dosing and follow-up. The study aims to enroll up to 10 patients, and these interim results include data from the first 5 patients with mild to moderate FTD who have completed the full course of treatment.Dr. Arun Swaminathan, Coya’s Chief Executive Officer followed: “The results thus far are consistent with previously published encouraging data from an open-label investigator-initiated study of patients with ALS treated with low-dose IL-2/CTLA4-Ig.  This interim data in FTD provides us further confidence of our approach to target and enhance Treg biology to address devastating neurodegenerative diseases including ALS and FTD”.Previous biomarker data presented by the Company demonstrated that FTD patients exhibit a compromised immunosuppressive function of regulatory T cells (Tregs), along with increased peripheral levels of inflammatory cytokines and chemokines, dysregulation of monocytes, and systemic activation of the inflammatory cascade, supporting the critical role of the immune system in the pathophysiology of FTD.One previous study showed that a cohort of 68 patients with FTD worsened by an average of 3.57 points over a 12-month period per the Clinical Dementia Rating - Frontotemporal Lobar Degeneration (CDR‐FTLD) scale (Knopman et al. Brain 2008; 131(11): 2957-2968). In addition, patients with FTD typically have shorter survival times and more rapid rates of cognitive and functional decline compared to patients with Alzheimer’s disease (Rascovsky et al. Neurology 2005; 65(3): 397-403).Dr. Fred Grossman, Coya’s Chief Medical Officer stated: “We are excited with the results observed in this initial group of patients with this proof-of-concept study.  We believe that the increase in Treg numbers and suppressive function, with subsequent anti-inflammatory biological activity still to be evaluated, underscores the potential for this low-dose IL-2/CTLA4-Ig combination to be further studied as a therapy for FTD, for which there are no currently approved treatments.”Summary of Interim Study Results      Overall, treatment with low-dose IL-2 and CTLA4-Ig was well tolerated.  All 5 patients enrolled in the first cohort completed the study and received the investigational treatment as planned.  The most common adverse events were mild injection site reactions. No serious adverse events were reported.Treg numbers and suppressive function increased after the first treatment cycle (p < 0.01 and p < 0.05, respectively, and remained at higher significant levels throughout the treatment period.Clinical functional assessments were performed in all patients at pre-specified timepoints over the course of the study using validated tools, including the Clinical Dementia Rating - Frontotemporal Lobar Degeneration (CDR‐FTLD) scale, the Montreal Cognitive Assessment (MoCA) scale, and the Progressive Aphasia Severity Scale (PASS).  Results of the functional tests show that, on average, these five FTD patients treated with low-dose IL-2 and CTLA4-Ig combination exhibited minimal to no cognitive decline over the course of the study, compared to pre-treatment values.The Company intends to publish and/or present more comprehensive data in a future peer-reviewed meeting and/or publication.About Frontotemporal DementiaFrontotemporal dementia (FTD) refers to a group of neurodegenerative disorders characterized by altered behavior and language, with a progressive decline in executive function.1 FTD affects an estimated 30,000 Americans.2 FTD is categorized clinically into various subtypes; the main three include behavioral-variant frontotemporal dementia and two language variants, semantic dementia (also known as semantic variant primary progressive aphasia) and progressive non-fluent aphasia (also known as non-fluent variant primary progressive aphasia).  It's a presenile dementia, meaning it can occur in younger individuals, often between the ages of 45 and 64. The average age of onset is 58, with an average survival time of 7.5 years.1,2References1. Knopman et al. Development of methodology for conducting clinical trials in frontotemporal lobar degeneration. Brain 2008; 131(11): 2957-29682. Rascovsky et al. Rate of progression differs in frontotemporal dementia and Alzheimer disease. Neurology 2005; 65(3): 397-403About Coya Therapeutics, Inc.Headquartered in Houston, TX, Coya Therapeutics, Inc. (Nasdaq: COYA) is a clinical-stage biotechnology company developing proprietary treatments focused on the biology and potential therapeutic advantages of regulatory T cells (“Tregs”) to target systemic inflammation and neuroinflammation. Dysfunctional Tregs underlie numerous conditions, including neurodegenerative, metabolic, and autoimmune diseases, and this cellular dysfunction may lead to sustained inflammation and oxidative stress resulting in lack of homeostasis of the immune system.Coya’s investigational product candidate pipeline leverages multiple therapeutic modalities aimed at restoring the anti-inflammatory and immunomodulatory functions of Tregs. Coya’s therapeutic platforms include Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.COYA 302 is a combination treatment comprised of low-dose IL-2 and CTLA4-Ig is an investigational therapy with a dual immunomodulatory mechanism of action intended to enhance the anti-inflammatory function of Tregs and suppress the inflammation produced by activated monocytes and macrophages. Coya is developing COYA 302 for the treatment of fatal neurogenerative diseases characterized by chronic inflammation and Treg dysfunction.For more information about Coya, please visit www.coyatherapeutics.com Forward-Looking StatementsThis press release contains “forward-looking” statements that are based on our management’s beliefs and assumptions and on information currently available to management. Forward-looking statements include all statements other than statements of historical fact contained in this presentation, including information concerning our current and future financial performance, business plans and objectives, current and future clinical and preclinical development activities, timing and success of our ongoing and planned clinical trials and related data, the timing of announcements, updates and results of our clinical trials and related data, our ability to obtain and maintain regulatory approval, the potential therapeutic benefits and economic value of our product candidates, competitive position, industry environment and potential market opportunities. The words “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” and similar expressions are intended to identify forward-looking statements.Forward-looking statements are subject to known and unknown risks, uncertainties, assumptions and other factors including, but not limited to, those related to risks associated with the success, cost and timing of our product candidate development activities and ongoing and planned clinical trials; our plans to develop and commercialize targeted therapeutics; the progress of patient enrollment and dosing in our preclinical or clinical trials; the ability of our product candidates to achieve applicable endpoints in the clinical trials; the safety profile of our product candidates; the potential for data from our clinical trials to support a marketing application, as well as the timing of these events; our ability to obtain funding for our operations; development and commercialization of our product candidates; the timing of and our ability to obtain and maintain regulatory approvals; the rate and degree of market acceptance and clinical utility of our product candidates; the size and growth potential of the markets for our product candidates, and our ability to serve those markets; our commercialization, marketing and manufacturing capabilities and strategy; future agreements with third parties in connection with the commercialization of our product candidates; our expectations regarding our ability to obtain and maintain intellectual property protection; our dependence on third party manufacturers; the success of competing therapies or products that are or may become available; our ability to attract and retain key scientific or management personnel; our ability to identify additional product candidates with significant commercial potential consistent with our commercial objectives; ; and our estimates regarding expenses, future revenue, capital requirements and needs for additional financing.We have based these forward-looking statements largely on our current expectations and projections about future events and trends that we believe may affect our financial condition, results of operations, business strategy, short-term and long-term business operations and objectives, and financial needs. Moreover, we operate in a very competitive and rapidly changing environment, and new risks may emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed herein may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. Although our management believes that the expectations reflected in our forward-looking statements are reasonable, we cannot guarantee that the future results, levels of activity, performance or events and circumstances described in the forward-looking statements will be achieved or occur. We undertake no obligation to publicly update any forward-looking statements, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.Investor Contact:David Snyder, CFOdavid@coyatherapeutics.com CORE IRBret Shapirobrets@coreir.com 561-479-8566Media ContactsFor Coya Therapeutics:Kati Waldenburgmedia@coyatherapeutics.com212-655-0924 Copyright 2025 ACN Newswire via SeaPRwire.com.

25 4 月, 2025

HighTide Therapeutics to Showcase New Analyses of Phase 2 MASH/T2DM Studies of Berberine Ursodeoxycholate (HTD1801) and Pre-Clinical Results of Rimtoregtide (HTD4010) in Presentations at EASL Congress 2025

HONG KONG, Apr 24, 2025 - (ACN Newswire via SeaPRwire.com) – HighTide Therapeutics, Inc. (2511.HK), a clinical stage biopharmaceutical company specializing in the development of multifunctional multi-targeted therapies for chronic liver and metabolic diseases, announced today that it will present at the EASL Congress 2025, taking place from May 7-10, 2025 in Amsterdam. The presentations include post-hoc analyses of two Phase 2 clinical studies of berberine ursodeoxycholate (HTD1801), a gut-liver anti-inflammatory metabolic modulator, being developed for treatment of metabolic dysfunction-associated steatohepatitis (MASH) and type 2 diabetes mellitus (T2DM). A third presentation will present preclinical results for rimtoregtide (HTD4010), a peptide derived from the Reg3a protein, in liver failure in mice.“Effects of Berberine Ursodeoxycholate (HTD1801) in Patients with At-risk MASH and T2DM”(Presentation SAT-440, Poster Presentation, May 10, 8:30 AM CET)About the Abstract: Due to the ongoing unmet medical need, clinical development in MASH focuses on patients who are at a higher risk of disease progression and outcomes due to the presence of moderate to advanced fibrosis (defined as at-risk MASH). The purpose of this analysis was to assess the effects of HTD1801 in patients with at-risk MASH and T2DM as defined by baseline MRI cT1 >875 ms. Eighteen weeks of treatment with HTD1801 resulted in substantial improvements in key hepatic and cardiometabolic parameters in patients with at-risk MASH and compared to placebo, twice as many patients achieved a reduction in liver fat content (MRI-PDFF) or fibroinflammation (cT1) that have been associated with improvements in liver histology. These data are particularly insightful as HTD1801 continues to be evaluated in an ongoing paired biopsy study of patients with at-risk MASH and pre-diabetes or diabetes.“Effects of Berberine Ursodeoxycholate (HTD1801) in Chinese Patients with T2DM and Presumed MASLD”(Presentation SAT-432, Poster Presentation, May 10, 8:30 AM CET)About the Abstract: T2DM typically coexists with other metabolic abnormalities such as hyperlipidemia, obesity, and MASH that can exacerbate T2DM and can lead to a worse prognosis with increased risk for mortality and cardiovascular outcomes. In a Phase 2 study in patients with T2DM, HTD1801 achieved the primary endpoint with a significant decrease in HbA1c. Based on the latest diagnostic criteria, it is likely that a substantial subgroup of the study may have had concurrent metabolic dysfunction-associated steatotic liver disease (MASLD). The purpose of this analysis was to evaluate the benefits of HTD1801 in patients with T2DM and MASLD identified by baseline controlled attenuation parameter values >288 dB/M (correlated to 5% liver fat content). HTD1801 treatment demonstrated both dose-dependent improvements in cardiometabolic and hepatic parameters in patients with T2DM and MASLD. These data suggest HTD1801 can comprehensively address metabolic and cardiovascular risk factors beyond glycemic control.“A Comparison of the Protective Effects of Rimtoregtide (HTD4010) and DUR-928 on Acute Liver Failure in Mice”(Presentation FRI-141, Poster Presentation, May 9, 8:30 AM CET)About the Abstract: The purpose of this study was 1) to test the potential protective effects of HTD4010 in an LPS-induced model mimicking acute liver failure in mice and 2) compare these effects to DUR-928, which is currently in late-stage development for the treatment of alcohol-associated hepatitis. In an LPS-induced mouse model mimicking acute liver failure, HTD4010 resulted in significant improvement in survival rates (greater than 2-fold) compared to the model control.  These protective effects of HTD4010 were significantly greater than DUR-928.  These findings provide evidence that HTD4010 may have a beneficial effect on acute liver conditions including alcohol-associated hepatitis and other acute-inflammatory-related conditions.About Berberine UrsodeoxycholateBerberine ursodeoxycholate (HTD1801) is an orally delivered, gut-liver anti-inflammatory metabolic modulator being developed for the treatment of metabolic and digestive diseases. HTD1801, an ionic salt of berberine and ursodeoxycholate, is a new molecular entity with a unique dual mechanism of action: AMP kinase activation and NLRP3 inflammasome inhibition. These two key mechanistic pathways have been associated with improvements in insulin resistance, glucose metabolism, lipid metabolism, and hepatic inflammation, potentially providing a comprehensive treatment platform for the multifaceted nature of complex metabolic diseases. HTD1801 is being developed for multiple indications. HTD1801 met the primary endpoint in two Phase 3 clinical trials in patients with type 2 diabetes mellitus (T2DM), demonstrating a clinically meaningful effect on HbA1c. In both trials, key secondary endpoints were achieved, suggesting multiple advantages of HTD1801 including improvement in cardiometabolic risk indicators. In addition to T2DM, HTD1801 efficacy in treating metabolic dysfunction-associated steatohepatitis (MASH) has been demonstrated in a Phase 2a clinical trial, and a global multicenter Phase 2b trial assessing the histologic benefit of HTD1801 is currently ongoing, with topline results expected in 2025.About RimtoregtideRimtoregtide (HTD4010) is a clinical-stage compound in development for acute inflammatory-related indications including alcoholic hepatitis (AH). It is a peptide derived from the Reg3a protein with immunomodulatory, anti-inflammatory, and anti-apoptotic effects. HTD4010 has been evaluated in animal models of acute pancreatitis and acute liver failure, where protective effects were observed. A completed Phase 1 clinical trial of HTD4010 in healthy subjects demonstrated a favorable safety profile. AH is caused by chronic heavy alcohol abuse or a sudden, drastic increase in alcohol consumption. It is characterized by severe inflammation and, ultimately, liver failure and death. There is currently no approved treatment for AH and only a few drug candidates are in clinical development. The current standard of care focuses on symptom management, including abstinence, treating inflammation and providing nutrition.About HighTide TherapeuticsHighTide Therapeutics, Inc. (Stock Code: 2511.HK) is a globally integrated biopharmaceutical company focusing on the discovery and development of first-in-class multifunctional, multi-targeted therapies with poly-indication potential across metabolic diseases with significant unmet medical needs. HighTide is currently developing several clinical assets and associated global intellectual property rights, and advancing multiple mid-to-late-stage clinical trials including therapies for metabolic dysfunction-associated steatohepatitis (MASH), type 2 diabetes mellitus (T2DM), severe hypertriglyceridemia (SHTG) and primary sclerosing cholangitis (PSC). Berberine ursodeoxycholate (HTD1801), HighTide’s lead drug candidate, received Fast Track designation from the United States Food and Drug Administration for both MASH and PSC and Orphan Drug designation for PSC. HTD1801 has been included in the National Major New Drug Innovation Program under the 13th Five-Year Plan for Major Technology Project in China.For more information, please visit www.hightidetx.comContact: pr@hightidetx.com Copyright 2025 ACN Newswire via SeaPRwire.com.

24 4 月, 2025

TransNusa Increases Scheduled Flight Frequency to Singapore

JAKARTA, Apr 24, 2025 - (ACN Newswire via SeaPRwire.com) - South East Asia’s first premium service airline, PT TransNusa Aviation Mandiri, is further strengthening its presence in Singapore by increasing the frequency of its scheduled flights for the Jakarta – Singapore route to two times daily from today.This announcement comes barely a month after TransNusa successfully launch scheduled flights to Perth from its base in Bali.TransNusa Group Chief Executive Officer, Datuk Bernard Francis said that TransNusa has plans to further strengthen its network connectivity this year.In line with this, TransNusa launched its second daily flight to Singapore today. The additional flight, 8B 153, departed at 12.10pm from the Terminal 3 Soekarno – Hatta International Airport and arrived Singapore Changi Airport at 14.40pm today. While its additional flight, 8B 154, departed Changi Airport at 15.30pm and arrived at the Soekarno – Hatta International Airport at 16.20pm.“TransNusa will continue to operate the current scheduled flight, 8B 151, which depart Soekarno – Hatta International Airport at 07.55am and arrive at 10.45am at the Changi Airport,” Datuk Bernard said, adding that the current flight, 8B 152, depart Changi Airport at 11.45am and arrive in Jakarta at 12.30pm.TransNusa has been consistently achieving milestones since the introduction of a new top management led by aviation veteran, Datuk Bernard Francis. The airline, which introduced its first international flight on April 14, 2023, has expanding its wings from South East Asia to the Asia Pacific region within a short span of 2 years.Datuk Bernard attributes the airline’s successes and accelerated growth within the last 24 months to their customised business model and the vastly experienced management team.Datuk Bernard stressed that for its international flights, TransNusa not only provide premium services with competitive ticket prices, but the airline also has attractive product bundles called SEAT, SEAT-PLUS and FLEXI-PRO."Our passengers will enjoy check-in baggage of between 20kgs to 30 kgs, depending on the product purchased,” Datuk Bernard said, explaining that the baggage offering was over and above the 7kgs limit offered as a passenger’s hand carry.“For the highest package, FLEXI-PRO, we provide more complete services such as free baggage 30kgs, free to choose seats, free food, and drinks, priority at check-in and boarding. In addition, TransNusa also provides its FLEXI-PRO passengers with the ability to be able to change their flight schedule without restrictions and obtain refund when needed.”TransNusa, which aims to ensure its passengers travel with ease and comfort, has also configured their A320s with a 174-seat configuration, which allows for passengers to enjoy about 30 inches of legroom, comparable to the experience passengers would get in a full-service airline."We are committed to providing affordable and competitive ticket prices, while still providing premium services to our customers.” said Datuk Bernard, adding that the ticket price for the Jakarta – Singapore route starts from as low as SGD52 (USD40).DATUK BERNARD FRANCIS… TransNusa to focus on strengthening network connectivityTransNusa, A Short HistoryTransNusa, which had to close it business operation in September 2020 due to impact of the Covid-19 pandemic on the aviation industry, started operations again after injection of new shareholders and a new management team led by aviation expert, Datuk Bernard, in October 2022.Within 6 months, the airline introduced its first international route between Jakarta and Kuala Lumpur and celebrated its first-year anniversary for this route on April 14, 2024.“When we re-launched TransNusa in October 2022, we started from the bottom again. Everything was new because the pandemic had disrupted the aviation business operations boundaries. As such we re-created and customised our business operations and strategy model of being the first Premium Service Carrier based on the post-pandemic scenario,” Datuk Bernard explained.TransNusa launched its first international route between Jakarta and Kuala Lumpur in April, 2023, followed by the Jakarta – Singapore route on November 20, 2023. After which, the airline successfully launched three more new international routes by the end of 2023. TransNusa’s aggressive international growth strategy combined with its domestic business operations approach has enabled the airline to experience strategic growth in the last two years.Since the takeover of new shareholders and the injection of a new management team, TransNusa has been making headlines in Malaysia, Singapore, China and Australia with news of being the first airline in Indonesia and the world to develop and introduce a new domestic route connecting Bali and Manado. TransNusa also became the second Indonesian airline to receive approval to fly to China.About TransNusaEstablished in 2005, TransNusa started its operation by providing chartered flights. It began its commercial flights in 2011. After ceasing operations due to the Covid-19 pandemic, TransNusa relaunched itself in 2021 as a low-cost airline in its domestic market. In 2023, TransNusa introduced a new business model making it the first Premium Service Airline in the region. The new business model will apply only to its international routes. TransNusa introduced its first international route in April this year. The airline introduced its Jakarta – Kuala Lumpur round trip route and had its maiden flight on April 14. The airline is currently based in Jakarta Soekarno-Hatta International Airport.Passengers can book their flights on the TransNusa website (www.transnusa.co.id), through authorized travel agents in Singapore and Indonesia, or by contacting the airline's customer service centre at, +62216310888. For the Singaporean market, passengers can contact TransNusa’s General Sales Agent, Chariot Travels Pte Ltd, at +65 86602719.Media ContactTrina Thomas Rajtrina@myqaseh.org+60124992672 (watsapp) Copyright 2025 ACN Newswire via SeaPRwire.com.

24 4 月, 2025

Waterloo Startup Axibo AI Secures $12M to Pioneer ‘Made in Canada’ Humanoids

WATERLOO, ONTARIO, Apr 23, 2025 - (ACN Newswire via SeaPRwire.com) - Axibo Inc., a Waterloo-based robotics innovator celebrated for its groundbreaking 4D volumetric capture technologies and serving customers like Netflix and Apple, today announced a $12 million funding round. This investment includes $11 million from prominent external investors and an additional $1 million from Axibo's founders Anoop Gadhrri, Sohaib Al-Emara, and Reiner Schmidt, whose passion for robotics began back in 2019 with their university's first autonomous vehicle. The funding launches Axibo's ambitious new division dedicated to advanced humanoid robotics.Axibo FoundersWith a track record of thousands of cinema robots delivered internationally, Axibo will now be leveraging Waterloo's exceptional AI, robotics, and precision engineering talent to spearhead advancements in humanoid robotics."We see humanoid robots as the next major milestone in productivity since the Industrial Revolution," said Anoop Gadhrri, co-founder and CEO of Axibo. "Canada is exceptionally well-positioned with its talent and resources. Our commitment is to drive this forward, placing Canada prominently on the global robotics stage."Axibo is actively seeking visionary engineers passionate about developing unprecedented technologies and shaping the global future of humanoid robotics. Early team members will not only create groundbreaking prototypes but directly contribute to substantial societal advancements through robots engineered for safe and intelligent integration into healthcare, logistics, industrial automation, and personal assistance. By fostering an innovation-driven culture emphasizing rapid prototyping and autonomy, Axibo empowers its engineers to experiment freely and iterate swiftly."We envision a future where every household benefits from humanoid robotics," Gadhrri emphasized. "Axibo's technology aims to significantly elevate productivity and everyday life across Canada and beyond."The company's immediate milestones include accelerating proprietary manufacturing processes, expanding its engineering and AI teams, and advancing capabilities in robot autonomy and dexterity. The new division's first robot prototype, temporarily code-named "T.E.B.", will debut in early 2026, demonstrating advanced agility and intelligence.If you're ready to build what's next in robotics, Axibo invites you to join the pioneering team positioning Canada at the global forefront of robotics innovation.To learn more or apply, visit axibo.ai.Contact InformationAnoop GadhrriCEOanoop@axibo.com6476675999SOURCE: Axibo Inc.Related Images Copyright 2025 ACN Newswire via SeaPRwire.com.

24 4 月, 2025

EdgePoint Towers advances renewable energy integration in telecommunications with first solar hybrid deployment

KUALA LUMPUR, Apr 23, 2025 - (ACN Newswire via SeaPRwire.com) - EdgePoint Towers Sdn Bhd (“EdgePoint”) – part of EdgePoint Infrastructure, a leading ASEAN-based independent telecommunications infrastructure company, has successfully launched its first solar hybrid site, marking a key milestone in its renewable energy initiatives. This deployment represents a significant step toward advancing sustainable energy solutions in Malaysia’s telecommunications sector.The new solution provides up to 100% of the energy required to operate telecommunications equipment, reducing dependence on diesel fuel. With a 5.9-kilowatt peak (kWp) capacity, the site operates autonomously using photovoltaic (solar) energy, complemented by battery storage.Muniff Kamaruddin, Chief Executive Officer of EdgePoint Towers, said, “We are proud to contribute to the deployment of renewable energy solutions that meet current and future needs for both sustainability and long-term cost efficiency. These solutions are especially important for remote and difficult-to-reach areas, such as transport corridors like highways, tunnels, bridges, or terminals, where quality coverage is essential for transient users. The opportunities to enhance national connectivity are vast, and EdgePoint is eager to continue working closely with our partners to advance sustainable solutions that improve coverage and reduce carbon emissions across the industry. This deployment is expected to reduce the site's annual carbon emissions by approximately 78%, while also ensuring seamless connectivity for travelers along the highway.”Muniff concluded, “Solar energy has proven to be an ideal solution for Malaysia, given its equatorial climate and high levels of solar insolation. By integrating solar power into telecommunications infrastructure, we are reducing reliance on non-renewable energy sources, lowering operational costs, and significantly decreasing emissions. Solar hybrid solutions are an adjacent focus area for us, it is a key part of our broader strategy of implementing innovative, sustainable solutions, driving an industry-wide transformation toward cleaner, more efficient operations and we are optimistic about future collaborations with both Mobile Network Operators (MNOs) and non-MNO clients to help them meet their green objectives. As we expand our renewable energy initiatives, we aim to set new benchmarks for energy-efficient telecom infrastructure in Malaysia, helping our partners transition to greener operations without compromising connectivity, network quality, and reliability.”By the end of 2025, EdgePoint plans to complete more full solar or solar hybrid sites across the country, further strengthening its commitment to sustainable telecom infrastructure.EdgePoint Infrastructure is the fastest-growing multi-country tower company in ASEAN, with 15,800 sites in its portfolio out of which 1,800 sites are in Malaysia making it the second-largest tower company in Malaysia.****ABOUT EDGEPOINT INFRASTRUCTUREEdgePoint Infrastructure is an ASEAN based independent telecommunications infrastructure company that aspires towards Building a Connected, Digital ASEAN. Headquartered in Singapore with operations in Malaysia, Indonesia and the Philippines, through EdgePoint Towers Sdn Bhd, PT Centratama Telekomunikasi Indonesia, Tbk and EdgePoints Towers Inc. respectively, the company is focused on providing sharable and leading-edge telecom structures, small cells and in-building systems. EdgePoint aims to be an industry leader through scale and innovation, driving operational efficiencies through the adoption of analytics and digital technologies. For more information on EdgePoint, please visit https://edgepointinfra.com/.  Copyright 2025 ACN Newswire via SeaPRwire.com.

24 4 月, 2025

Batch Bicycles and Hyatt Place Zhuhai jointly organized An Exhalating Cycling Event in Macau

HONG KONG, Apr 23, 2025 - (ACN Newswire via SeaPRwire.com) – On 22 April, Earth Day, an electrifying cycling event was held across Guangdong and Macau. Batch Bicycles and Hyatt Place Zhuhai jointly organised Ride Macao, an event to explore the country on wheels and celebrate Earth's Day with green travel.In today’s fast-paced city life, people are often busy with work and various affairs that they gradually leave nature and sports behind. The Ride Macao event was designed to break this shackle and spread the values of living green, protecting the environment and the cycling lifestyle to everyone.Starting from Hyatt Place Zhuhai and arriving at Hengqin Port, the carefully planned route combined the picturesque natural scenery and unique cityscape along the way with the ease of cruising through customs. Riders enjoyed the magnificent view of the sea and sky during the journey while also experiencing the unique charm of the blend of history and modernity found along the streets and lanes of Macau. This was not only a long-distance ride, but also a deep dialogue with the earth to embrace green living.Ride Macau by Batch Bicycles (a brand of Covation)Batch Bicycles Products DisplayBatch Bicycles is a global brand of Covation Holdings Limited (Covation). Covation is a global holding company headquartered in Hong Kong. Covation's vision of consumer-centric innovation is driven by its diverse portfolio of outdoor brands, including Huffy, Niner Bikes, Batch Bicycles, Royce Union, VAAST and Buzz E-Bikes, which are available to consumers in more than 50 countries and territories around the world through an extensive global distribution network.  The company ships more than 5 million bicycles annually. Covation holds a wide-ranging licensing portfolio with world-class partners such as Disney, Marvel, Lucasfilm, National Geographic, Ford, Nickelodeon, Hasbro, and Panama Jack. The vast distribution network includes leading global retailers such as Walmart, Amazon, Target, Swire, Big W, Academy, Argos, Smyths, and many other international outlets.The mission of Batch Bicycles is to 'make cycling easier'. With a wide range of products including mountain bikes for conquering mountains, road bikes for riding the pavement, gravel bikes and cycling equipment specially designed for teenagers. Batch Bicycles are designed to provide cycling enthusiasts around the world with a comfortable and smooth cycling experience through innovative designs and high-quality configurations. The Macao Ride is a vivid manifestation of Batch Bicycles brand philosophy to make cycling easier and encourage people to venture out of the concrete city to explore the world and embrace nature through cycling. Copyright 2025 ACN Newswire via SeaPRwire.com.

24 4 月, 2025

The 3rd International & Indonesia CCS Forum 2025: A Global Collaboration Momentum for CCS Development

JAKARTA, Apr 21, 2025 - (ACN Newswire via SeaPRwire.com) - The Indonesia Carbon Capture and Storage Center (ICCSC) is organizing The 3rd International & Indonesia CCS Forum 2025, an international-scale forum aimed at accelerating the development of Carbon Capture and Storage (CCS) technology as a key pillar toward a green economy and sustainable growth in Indonesia. The event will take place on October 7-8, 2025, at Hotel Mulia, Jakarta, featuring over 100 global speakers from various sectors.Belladonna Troxylon Maulianda, Executive Director of ICCSC, emphasized that this forum is designed as a strategic platform to bring together global stakeholders, including governments, industry players, academics, and investors. "CCS plays a crucial role in reducing carbon emissions and supporting Indonesia's net-zero targets. Through this forum, we aim to strengthen global collaboration to address challenges and leverage opportunities in CCS development," said Belladonna.The forum's theme, "Advancing Indonesia as a CCS Hub Leader in the Asia Pacific: Achieving Net Zero and Economic Growth", reflects a shared commitment to driving sustainable growth through clean energy. "We hope this event will generate innovative solutions and policy recommendations to accelerate CCS development in Indonesia and globally," she continued.Evan Lukas, Chairman of the Organizing Committee for The 3rd IICCS Forum 2025, explained that this event will feature various exciting programs, including high-level panel discussions, exhibitions of the latest technology, and strategic networking sessions. "This forum is not only a platform for sharing knowledge but also a place for the birth of strategic partnerships and innovative solutions to global challenges in CCS development," said Evan."We invite all stakeholders, including the government, industry players, and the community, to actively participate in this forum. Together, we can build a network of regional CCS hub towards a low-carbon future and support energy transition" added Evan.ICCSC hopes this forum can become a catalyst for strengthening Indonesia's position as a global leader for regional CCS hub that decarbonize heavy industries, while continuing to meet energy demand and grow economies.Elen Setiadi, Deputy Minister for Energy and Mineral Resources, Coordinating Ministry for Economic Affairs of The Republic of Indonesia expressed appreciation for the forum's organization. "The government fully supports this event as part of efforts to achieve energy transition and net-zero emission targets. CCS is one of the key solutions in Indonesia's clean energy transition," said Elen.The 3rd International & Indonesia CCS Forum 2025 also offers participants the opportunity to interact directly with industry leaders, experts, and policymakers. In addition to the main programs, the event will showcase the latest CCS technology exhibitions featuring innovations from global companies.The ICCSC invites all stakeholders, including strategic partners, industry associations, government representatives, and media, to join this forum. The event is not only a moment for discussion but also for taking concrete steps toward realizing a sustainable clean energy future.For more information on The 3rd International & Indonesia CCS Forum 2025, visit the official website: www.iiccsforum.com About IICCSThe International & Indonesia Carbon Capture and Storage Center (IICCS) is a platform dedicated to promoting CCS technology and facilitating collaboration between governments and industries in addressing climate change through CCS implementation. About ICCSCThe Indonesia Carbon Capture and Storage Center (ICCSC) is a community of experts from various industry, including engineering, science, policy, and business, united by a shared commitment to finding practical solutions to CO2 emission challenges. Through research, innovation, and advocacy, we strive to accelerate carbon capture and storage development in Indonesia and position the country as a Regional CCS Hub. Visit iccscenter.com.Media Contact:info@iccscenter.com+62 878 8721 3208 Copyright 2025 ACN Newswire via SeaPRwire.com.

23 4 月, 2025

Earth Day Special: foundit Report Reveals 27% Surge in Green Jobs as Singapore Accelerates Sustainability Push

Key Highlights:- Green jobs in Singapore show 27% year-on-year growth with 12% month-on-month increase in March '25- Engineering, Construction & Infrastructure sector leads sustainability hiring with 29% share of green jobs- Consulting & Strategy sector accounts for 11% of sustainability-focused positions- ESG Analyst emerges as the role with the highest growth in demand 28% year-on-year - Singapore's green job sector projected to grow by 11% in 2025SINGAPORE, Apr 23, 2025 - (ACN Newswire via SeaPRwire.com) - Jobs platform, foundit (formerly Monster APAC & ME), today published the foundit Earth Day Special Singapore Report as part of the foundit Insights Tracker (fit). The report highlights significant growth in sustainability-driven hiring across Singapore's employment landscape.The tracker reveals an overall year-on-year (YoY) growth of 27% in green jobs, with a positive month-on-month (MoM) increase of 12% in March 2025, building on the 17% growth seen in February."Singapore’s green job market is witnessing remarkable growth," said V Suresh, CEO of foundit. "Our Earth Day Special report reveals a 27% year-on-year surge in green job opportunities, underscoring the nation’s steadfast commitment to sustainability and environmental stewardship. Pivotal sectors such as Engineering, Construction, and Sustainable Finance are spearheading this transition, driving substantial and lasting impact. This upward trend not only mirrors the evolving demands of the labour market but also resonates strongly with the objectives of Singapore’s Green Plan 2030, reaffirming sustainability as a cornerstone of the country’s long-term economic vision.”Engineering, Construction and Consulting sectors lead sustainability hiringThe Engineering, Construction & Infrastructure sector has emerged as the frontrunner in sustainability-focused hiring, accounting for 29% of all green job opportunities across monitored industries. This dominance reflects Singapore's commitment to eco-friendly urban development and sustainable infrastructure projects. Representing 11% of green job postings, the Consulting & Strategy sector is gaining momentum, driven by growing demand for sustainability consultants and environmental strategists as organisations integrate ESG frameworks into their operations.Education and Manufacturing & Production sectors each contribute 7% of sustainability-focused positions, highlighting increased focus on workforce reskilling and the transition toward cleaner production practices.Energy and Research & Technology sectors each account for 6% of green job opportunities, supporting innovations in renewables, green hydrogen, and sustainable R&D initiatives across Singapore.ESG and Renewable Energy professionals lead demand among sustainability rolesIn terms of sustainability-focused roles, ESG Analysts witnessed the highest growth with a 28% year-on-year increase, underscoring the rising importance of environmental, social, and governance considerations in business operations.Sustainability Consultants followed closely with 24% year-on-year growth, while Renewable Energy Engineers showed strong demand with 22% year-on-year growth, reflecting Singapore's push toward clean energy alternatives.Other high-growth roles include Green Supply Chain Managers (+19%), Environmental Policy Officers (+16%), Carbon Credit Analysts (+14%), and Climate Risk Specialists (+13%), indicating broad demand across sustainability functions.The report highlights evolving skill requirements, with employers increasingly seeking cross-functional expertise that blends engineering, finance, policy, and digital proficiency to meet regulatory and ESG expectations.Looking ahead, the green job sector in Singapore is projected to grow by 11% in 2025, with renewable energy, electric mobility, and green infrastructure identified as key growth drivers.The foundit Insights Tracker is a comprehensive monthly analysis of online job posting activity conducted by jobs platform, foundit. Based on a real-time review of millions of employer job opportunities culled from a large, representative selection of online career outlets, the foundit Insights Tracker (FIT) presents a snapshot of employer online recruitment activity nationwide.About foundit - APAC & Middle Eastfoundit, formerly Monster (APAC & ME), is Asia’s leading jobs and talent platform offering comprehensive employment solutions to recruiters and job seekers across APAC & ME. In addition to its innovative AI-powered job search, foundit offers e-learning, assessments, and services related to resume creation and interview preparation. foundit has connected over 120 million job seekers across 18 countries with the right job roles and upskilling opportunities. Over the last two decades, the company has been a leader in the world of recruitment solutions and has launched cutting-edge tools to give recruiters access to passive candidates in addition to active ones. With its advanced technology, foundit is efficiently bridging the talent gap across industry verticals, experience levels, and geographies.Today, foundit is committed to enabling and connecting the right talent with the right opportunities by harnessing the power of deep tech to sharpen hyper-personalised job searches and offer precision hiring.To learn more about, foundit in APAC & Gulf, visit: www.foundit.sg |www.foundit.com.ph | www.foundit.my | www.foundit.in | www.founditgulf.com | http://www.foundit.hk | www.foundit.id For media inquiries or further information, please contactNamrata SharmaNamrata.sharma@adfactorspr.comContact number - +65 81383034 Copyright 2025 ACN Newswire via SeaPRwire.com.

23 4 月, 2025

CIRC: Attained a New High in Fiscal Year 2024

HONG KONG, Apr 22, 2025 - (ACN Newswire via SeaPRwire.com) – In recent years, with the launch of top-level design for nuclear medicines and the implementation of supporting policies, the domestic nuclear medicine industry has ushered in a golden period of development. According to the data analysis of BCC Research, there will be a growth in the global nuclear medicine market from $12.6 billion in 2023 to $21 billion by the end of 2029, with a compound annual growth rate (CAGR) of 8.29% during the forecast period from 2024 to 2029. Meanwhile, Medraysintell, a market intelligence agency specializing in radiotherapy and nuclear medicine, predicts that there will be a growth of about $30 billion in the global nuclear medicine market in 2030.As a leading nuclear medicine company in China, CIRC (01763.HK) recently disclosed its annual report for 2024 as of December 31st. In 2024, CIRC achieved a remarkable growth in revenue and net profit, which not only delivered a satisfactory answer on the performance level, but also showed a strong technical transformation capability in nuclear medicine research and development.Year-by-year growth facilitated nuclear medical equipment to become a new engineAccording to the financial data, CIRC achieved revenue of RMB 7.575 billion in 2024, with a year-on-year increase of 14.2%, and the net profit of RMB 880 million, with a year-on-year increase of 13.3%.From the perspective of branch business, all fields have blossomed in an all-round way. As the core pillar of the company, the nuclear medicine business achieved revenue of RMB 4.168 billion, accounting for 55% of the total revenue. Among them, the income of imaging diagnosis and therapeutic radiopharmaceuticals increased by 4.1% year-on-year, and the distribution of medical centers all over the country achieved remarkable results. The income of Technetium-labeled medicines increased by 8.7% year-on-year. The breath test business continued to maintain a stable high market share, achieving revenue of RMB 2.35 billion, by a year-on-year increase of 1.1%.It is worth noting that in 2024, CIRC accelerated the localization of high-end radiotherapy equipment, and nuclear medical equipment and related services became the new engine of growth, with revenue reaching RMB 1.223 billion, a year-on-year increase of 31.0%. The new generation of Precision radiation therapy planning system was successfully approved for medical device registration certificate, and the world’s first spiral tomotherapy system, Tomo C, was delivered to Shandong Cancer Hospital for installation, which was successfully selected intothe 2024 high-end medical equipment promotion and application project of two ministries and commissions (Ministry of Industry and Information Technology/National Health Commission) and Tianjin First (Set) Major Technical Equipment Promotion and Application Guidance Catalog (Version 2024), with sales during the year leading in the domestic market.CIRC recorded RMB 716.1 million in revenue from radioactive source products, representing a year-on-year increase of 22.2%. Gamma knife source and non-destructive testing radioactive source continued to maintain a stable and high market share. CNNC Qinshan Isotope successfully obtained the Class A radiation safety license, and the cobalt-60 radioactive source production line delivered 2 million curies.40-year solid accumulation in nuclear technology laid a solid foundationAs the main body of the nuclear technology application industry of CNNC, CIRC has been accumulated in the industry for over 40 years, forming a “6+N” industrial layout with six major businesses as the core, including nuclides, nuclear medicines, nuclear medical equipment, integrated solution for nuclear medicine, radioactive source and application, and irradiation application. During the Reporting Period, CIRC achieved 224 patent authorizations, with a total of 969 valid patents, and continued to maintain the leading position of the R&D investment intensity in the industry.In the field of nuclear medicine research and development, CIRC has demonstrated a strong technical capability from research results turned into technologies. Sodium fluorine-18 injection obtained the drug registration certificate from the National Medical Products Administration and was approved for marketing, filling the market gap of PET diagnostic imaging agent in the field of bone imaging in China. Iodine-131-MIBG injection is close to the end of Phase III clinical trial. After the drug is launched, it will provide a new diagnostic method for neuroendocrine tumors such as pheochromocytoma and neuroblastoma. It is worth noting that CIRC has proactively laid out integrated diagnosis and treatment drugs, and the research and development of Lutetium-177oxyoctreotide injection is progressing smoothly, marking a strategic upgrade from simple diagnosis to precise diagnosis and treatment.In addition to stabilizing the base of nuclear medicine, CIRC has gradually increased its emphasis on nuclear medical equipment. According to the sales data in recent years, the income of nuclear medical equipment has steadily increased. In 2024, a new generation of Gamma Knife was approved, which integrated CBCT image guidance, six-dimensional bed auto-correction, and other intelligent technologies, and the treatment efficiency was improved by 30%. In the Class A large-scale medical equipment market, CIRC occupies an absolute dominant position through its holding subsidiary, CNNC ACCURAY. In February this year, 19 of the 28 high-end radiotherapy equipment in the second round of Class A large-scale medical equipment licensing list released by the National Health Commission came from CNNC ACCURAY, accounting for 68% of the market. It is worth noting that the breakthroughs in the fields of Cobalt-60-based Stereotactic Therapy System also promote the localization of radiotherapy equipment.Facing the explosive growth of the nuclear medicine market, CIRC Accelerated Pharmaceutical Center continues to expand its nationwide network layout. In 2024, a new positron emission drug production line has been added in Lanzhou, with a total of 23 lines put into operation; Newly added Fuzhou Technetium Drug Production Line, with a total of 27 units put into operation. CIRC has built the first 10,000 Curie level lutetium-177 production line and a thousand level germanium-gallium [68Ge-68Ga] generator production line in the country, achieving a breakthrough in the localization of high-end nuclides.It is worth noting that CIRC has created a hierarchical innovation ecosystem through the "Parent-Subsidiary Collaboration" model. In 2024, its subsidiaries, CNNC HEADWAY (breath test) and CNNC Chengdu Gaotong (nuclide), were awarded the national level specialized, refined, and new "little giants" enterprise, bringing the total number of specialized, refined, and new enterprises under CIRC to 18. Among them, CNNC HEADWAY dominates the breath testing market with its integrated solution of "medicine box+instrument", while CNNC Chengdu Gaotong has become a benchmark in the field of nuclear technology application through its full chain layout of "Nuclide-Drug-Equipment". This innovative system, resembling an "Aircraft carrier battle group", provides sustainable momentum for the company's long-term growth.Expanding Development Space with Globalization LayoutAs the main force of CNNC Group's march towards people's life and health science and technology and the main channel for the transformation of advanced nuclear science and technology achievements, CIRC responds to the Group's "Overall&Coordination" internationalization strategy and the national "the Belt and Road" initiative, vigorously promotes the internationalization strategy and constantly expands overseas markets. By 2024, the export revenue will reach RMB 627 million, and the products will be exported to dozens of countries and regions such as Brazil, Peru, and Nigeria.At the beginning of this year, we successfully signed a contract for the supply of equipment for a million curies design source gamma irradiation station in Bangladesh. This is another equipment supply project for irradiation stations that has landed after winning the bid for the Bangladesh Institute of Nuclear Agriculture's design source gamma irradiation station project in 2024. After its completion and operation, the irradiation station will mainly serve the irradiation sterilization of medical products in Bangladesh, significantly improving the quality level and production processing capacity of local medical products, assisting the development of Bangladesh's medical industry, and benefiting local people's livelihoods.In Nigeria, CIRC successfully signed a contract for the overall supply of nuclear medical equipment, achieving the first successful landing of the Group's nuclear medical equipment overall supply project. In addition, CIRC actively expands into the ASEAN market and successfully exports cold chain drugs to Thailand; We have also signed strategic cooperation agreements with multiple entities in Brazil to support the signing of a memorandum of understanding on strategic cooperation in the field of nuclear technology applications between the National Atomic Energy Agency and Brazil.ConclusionAgainst the backdrop of policy support and sustained market demand, CIRC stated to focus on the "Do as the Demard of the Country" and further deepen the coordinated development of nuclear medicine and high-end equipment around the "Healthy China" strategic framework. According to its 2025 plan, key projects such as Qinshan Isotope Base, Phase I of Jiajiang Radioactive Source Base, and Phase I of North China Pharmaceutical Base will be promoted according to milestones, involving nuclide production, radioactive source manufacturing, and pharmaceutical supply chain layout. At the same time, CIRC will enhance its digital diagnosis and treatment service capabilities through the iteration of smart nuclear medicine projects, and plans to launch no less than 3 intelligent systems within this year.At the international level, CIRC will continue the market expansion strategy along the "the Belt and Road", rely on the existing business models such as radiation station equipment export, nuclear medical equipment overall solution output, focus on the cooperation in South America, Southeast Asia, the Middle East, North Africa and other regional markets, and further improve the global market penetration rate in the future or through localized cooperation.The management of the Company stated that in 2025, CIRC will continue to strengthen technological innovation, improve the modern industrial system, accelerate the cultivation and development of new quality productivity, continuously enhance core functions, improve core competitiveness, and accelerate the establishment of an internationally-renowned supply group of technology, product and service in isotope and radiation. Copyright 2025 ACN Newswire via SeaPRwire.com.

23 4 月, 2025

2025 U.S. Open Polo Championship Final Concludes American High-Goal Season, Supported by U.S. Polo Assn.

WELLINGTON, FL, Apr 22, 2025 - (ACN Newswire via SeaPRwire.com) - The 2025 U.S. Open Polo Championship®, played at the USPA National Polo Center (NPC) in Palm Beach County, showcased top-tier polo action from March 26 to April 20 and ended this Sunday with a thrilling Final win by La Dolfina Tamera over La Dolfina Catamount in a score of 12-8 in front of a record crowd.Agustina FondaLa Dolfina Tamera wins the U.S. Open Polo Championship® trophy.Watch the U.S. Open Polo Championship on ESPNHosted by legendary ESPN broadcaster Chris Fowler, the U.S. Open Polo Championship Final was played on the U.S. Polo Assn. Stadium Field, in front of an electric crowd. The game will be broadcast to a large global audience across multiple ESPN platforms, including ESPN2 on Saturday, April 26, at 10:30 AM EDT, as well as Primetime on ESPNews on Sunday, April 27. Check your local listing for air times.U.S. Polo Assn. Supports the Sport and Equine CharitiesAs the sport's most prestigious tournament in North America, the U.S. Open Polo Championship features some of the world's best polo players and equine athletes. Once again, the tournament was supported by U.S. Polo Assn., the official brand of the United States Polo Association (USPA), with U.S. Polo Assn. branded jerseys for teams, NPC staff uniforms, umpire outfitting, player prizes, and monetary donations to several local charities. Throughout the season, the global, sport-inspired brand has donated some $25,000 to polo charities and equine welfare, among others, including Homes for Horses Coalition, Museum of Polo and Hall of Fame, Polo for Life, Polo Players Support Group, Polo Pony Rescue, Polo Training Foundation, Replay Polo, Retired Racehorse Project, Vinceremos Therapeutic Riding Center, and Work to Ride Program."U.S. Polo Assn. is proud to once again support the U.S. Open Polo Championship, broadcast on ESPN platforms as one of the top sporting events of the Spring season alongside the Masters and Kentucky Derby," said J. Michael Prince, President and CEO of USPA Global, the company that manages and markets the multi-billion-dollar U.S. Polo Assn. brand. "It's an honor to have legendary ESPN broadcaster Chris Fowler as the host this year, alongside Kenny Rice and Adam Snow, bringing more access and awareness to the sport of polo as we continue to reach more and more sports fans and consumers around the world."An Electric Game Watched Live by a Record-Breaking CrowdThousands of fans at NPC witnessed the action-packed final game of the Gauntlet of Polo® tournament series, which included the C.V. Whitney Cup®, the USPA Gold Cup®, and the U.S. Open Polo Championship. In a year that delivered record-breaking crowds week in and week out, the thrilling final was filled with great plays from the world's best players on both teams, La Dolfina Tamera featuring 10-goal player Adolfo Cambiaso; Diego Cavanagh; Matt Coppola; and Alejandro Poma, and La Dolfina Catamount featuring 10-goal player Poroto Cambiaso; Jesse Bray; Rufino Merlos and Scott Devon. For the second year in a row, the U.S. Open Polo Championship Final presented an epic showdown between two of the world's top polo players who are also father and son.Adolfo, age 50, who has been defeated in the last two U.S. Open Finals, the last one being to his son, Poroto, age 19, reclaimed victory in this game to take home his 10th U.S. Open title. It was just this week that Adolfo turned 50, thus reclaiming the championship trophy as his perfect birthday present. Adolfo is considered the best polo player in history, having also won more than 17 titles in the Argentine Open Polo Championship, and is considered the "Greatest of All Time (GOAT)" beside other sports icons such as Tiger Woods, Michael Jordan, and Tom Brady.Adolfo Cambiaso, Age 50, Defeats Son Poroto Cambiaso, Age 19, Wins Back TrophyLa Dolfina Catamount came out strong at the beginning of chukker 1, but La Dolfina Tamera soon took the momentum and kept the game close. The score was tied at 6-6 after the 3rd chukker. After some clutch goals by Poma in chukkers 3,4, and 5 and an impressive long goal from Adolfo, Tamera continued to have the lead. Though Poroto scored an incredible 5 goals overall, and Bray scored in the 6th and final chukker, both of Catamount, to bring it to 11-8, there just wasn't enough time for a comeback. Tamera clinched their win with a thrilling goal by Coppola to make the final score 12-8. La Dolfina Tamera's Poma won MVP, scoring a team-high 4 goals, with Adolfo scoring 3 goals."Congratulations to La Dolfina Tamera on a remarkable victory in the U.S. Open Polo Championship," said Stewart Armstrong, Chairman of the USPA. "I would also like to thank and acknowledge all participating teams throughout the 2025 Season at NPC for leaving it all on the field for the sport.""Thank you to all of our patrons, players, sponsors, and sports fans for their passion and support for the sport of polo and the USPA this season," Armstrong added.The USPA National Polo Center, the Winter Equestrian Capital of the WorldGuests at NPC, the world's premier polo facility based in Palm Beach County, watched the action-packed match from many luxurious settings, including the sidelines, stadium boxes, tailgate tents, the grandstands, as well as from the U.S. Polo Assn. MVP Lounge, home to the iconic Sunday Polo Brunch. Sports fans also had exclusive on-site shopping opportunities at the flagship USPA Shop location, where limited-edition sport-luxury pieces in The Polo Club Collection and the U.S. Polo Assn. Global Collection were available for fans wanting to take home a piece of the sport of polo. New this year included a 4ocean branded custom-designed bracelet, an element of the longstanding partnership between the two brands, with 4Ocean being the Official Recycling Partner of the 2025 U.S. Open Polo Championship.Photo Credits: Agustina FondaLa Dolfina Tamera wins the U.S. Open Polo Championship® trophy.La Dolfina Tamera's Adolfo Cambiaso hooks the mallet of his son Poroto Cambiaso of La Dofina Catamount in a defensive play to ultimately win the U.S. Open Polo Championship® in a score of 12-8.The record-breaking crowd at the USPA National Polo Center (NPC) watching the heart-pounding U.S. Open Polo Championship® Final.About U.S. Polo Assn. and USPA GlobalU.S. Polo Assn. is the official brand of the United States Polo Association (USPA), the largest association of polo clubs and polo players in the United States, founded in 1890 and based at the USPA National Polo Center in Wellington, Florida. This year, U.S. Polo Assn. celebrates 135 years of sports inspiration alongside the USPA. With a multi-billion-dollar global footprint and worldwide distribution through more than 1,100 U.S. Polo Assn. retail stores as well as thousands of additional points of distribution, U.S. Polo Assn. offers apparel, accessories, and footwear for men, women, and children in more than 190 countries worldwide. Historic deals with ESPN in the United States and Star Sports in India now broadcast several of the premier polo championships in the world, sponsored by U.S. Polo Assn., making the thrilling sport accessible to millions of sports fans globally for the very first time.U.S. Polo Assn. has consistently been named one of the top global sports licensors in the world alongside the NFL, NBA, and MLB, according to License Global. In addition, the sport-inspired brand is being recognized internationally with awards for global and digital growth. Due to its tremendous success as a global brand, U.S. Polo Assn. has been featured in Forbes, Fortune, Modern Retail, and GQ as well as on Yahoo Finance and Bloomberg, among many other noteworthy media sources around the world.For more information, visit uspoloassnglobal.com and follow @uspoloassn.USPA Global is a subsidiary of the USPA and manages the global, multi-billion-dollar U.S. Polo Assn. brand. Through its subsidiary, Global Polo Entertainment (GPE), USPA Global also manages Global Polo TV, which provides sports and lifestyle content. For more sports content, visit globalpolo.com.Contact InformationShannon StilsonVP, Sports Marketing & Mediasstilson@uspagl.com+001.561.227.6994Stacey KovalskyVice President, Global PR and Communicationsskovalsky@uspagl.com+001.561.790.8036SOURCE: U.S. Polo Assn.Related ImagesAgustina FondaLa Dolfina Tamera’s Adolfo Cambiaso hooks the mallet of his son Poroto Cambiaso of La Dofina Catamount in a defensive play to ultimately win the U.S. Open Polo Championship® in a score of 12-8.Agustina FondaThe record-breaking crowd at the USPA National Polo Center (NPC) watching the heart-pounding U.S. Open Polo Championship® Final. Copyright 2025 ACN Newswire via SeaPRwire.com.

22 4 月, 2025

Everest Medicines Announces Approval of ‘B’ Marker Removal from Company’s Stock Code by the Hong Kong Stock Exchange

SHANGHAI, Apr 22, 2025 - (ACN Newswire via SeaPRwire.com) – Everest Medicines (HKEX 1952.HK, “Everest”, or the “Company”), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced that The Stock Exchange of Hong Kong Limited (the “Stock Exchange”) has approved the Company’s application to remove the “B” marker from its stock short name, as the company has satisfied the requirements of the listing rules at the Stock Exchange. “We are very pleased that Everest Medicines has satisfied the market capitalization/revenue test under Rule 8.05(3) of the Listing Rules and successfully removed the 'B' marker - a significant milestone for the Company in the capital markets that could lead to wider investor participation.” said Rogers Yongqing Luo, Chief Executive Officer of Everest Medicines. "Moving forward, we will continue to deepen our 'dual-engine strategy', enhancing our commercial excellence and advance our first-in-class and best-in-class assets with global rights to maximize synergies. With global rights to EVER001, we will actively explore partnership opportunities outside of China to leverage international expertise and optimize commercial value, while further enhancing Everest’s global visibility and presence. Everest will leverage its established efficient commercial platform to solidify our position in key therapeutic areas, advance innovation on our mRNA platform, and strive to become a leading biopharma in the Asia-Pacific region by 2030.The removal of the “B” marker reflects a comprehensive evaluation of Everest Medicines’ robust R&D pipeline, commercialization capabilities, and overall business fundamentals. Listed on the Stock Exchange in October 2020, Everest has adopted a “dual-engine” strategy, focusing on high-value therapeutic areas while striving to develop first-in-class or best-in-class innovative treatments. The company has established a strong and synergistic platform across nephrology, infectious diseases, and autoimmune diseases, with three commercialized products already driving rapid revenue growth.According to the company’s 2024 financial results, total revenue reached RMB706.7 million, representing a 461% year-over-year increase and exceeding our revenue guidance of RMB700 million, and achieved commercial-level profitability for the full year of 2024.NEFECON®, as the only approved IgAN therapy in China, generated RMB353.4 million in revenue for the year, representing a year-over-year increase of 1,581%. NEFECON® was also included in China’s National Reimbursement Drug List (NRDL), effective January 1, 2025. As the first-in-class fluorocycline antibiotic, XERAVA® (eravacycline) maintained robust growth with generated RMB352.8 million in revenue in 2024, representing a 256% year-on-year increase. VELSIPITY® (etrasimod), a best-in-class therapy for autoimmune diseases, has been received regulatory approvals in Macau and Singapore, the product was subsequently commercially launched in December in Guangdong province under the “Hong Kong and Macau Medicine and Equipment Connect” policy. In parallel, New Drug Applications (NDAs) for VELSIPITY® have been officially accepted in both mainland China and Hong Kong in December 2024.EVER001, for which Everest holds global rights, delivered positive results from the preliminary analysis of our Phase 1b/2a trial and is progressing steadily through global development. EVM16, our personalized therapeutic mRNA cancer vaccine, completed first patient dosing in an investigator-initiated clinical trial (IIT) in March 2025. EVM14, our off-the-shelf tumor-associated antigen (TAA) vaccine, received Investigational New Drug (IND) approval from the U.S. FDA, and we plan to submit an IND application to China’s NMPA in the first half of this year. The in vivo CAR-T program is expected to achieve preclinical candidate milestone later this year. These programs are supported by our commercial-scale, GMP-compliant manufacturing facility in Jiashan, Zhejiang, which provides integrated R&D, production, and commercialization capabilities across mRNA and other pipeline platforms.  Copyright 2025 ACN Newswire via SeaPRwire.com.

22 4 月, 2025

Moolec Science Enters Into Transformational Transaction Expanding Across Multiple Technology Platforms

Luxembourg, Apr 21, 2025 - (ACN Newswire via SeaPRwire.com) - Moolec Science SA (NASDAQ:MLEC) ("The Company" or "Moolec"), a science-based food ingredient company focused on producing animal proteins and nutritional oils in plants, today announced that it has entered into a Business Combination Agreement (the "BCA") with Bioceres Group Limited ("Bioceres Group") and other related entities in an all-stock transaction (the "Business Combination"). Subject to the terms and conditions of the BCA, which was signed on April 17, 2025, several parties will transfer their respective holdings in Bioceres Group, Nutrecon LLC ("Nutrecon"), and Gentle Technologies Corp ("Gentle Tech", and together with Bioceres Group and Nutrecon, the "Contributed Entities"), resulting in an enlarged corporate structure with Moolec as the parent company. In exchange, Moolec will issue a combination of up to 87 million newly issued shares and 5 million warrants to the shareholders of the Contributed Entities, as more fully described below in the Timing and Approvals section.Federico Trucco, Bioceres Group's board member and CEO of Bioceres Crop Solutions Corp commented: "The need to accelerate agricultural innovation to address current and future challenges, such as enhancing on-farm profitability and reducing environmental impact, is increasingly evident. Molecular farming, as exemplified by Moolec Science, offers a compelling solution to the challenge of balancing productivity and sustainability. For instance, what soybean yield technology can rival the direct production of 300kg of animal protein from a 3-ton-per-hectare crop?" He then finished: "Moolec's recent transformational transaction represents the kind of bold action needed to drive radical change in agriculture. Integrating technologies and capabilities, along with a holistic perspective on agricultural evolution, are essential for moving beyond incremental improvements. Scale and visibility, both of which are key aspects of this transaction, are crucial to achieving this goal. Bioceres is enthusiastic to be part of a larger, more ambitious Moolec, one that expands its focus from science in food ingredients to a comprehensive ‘cradle-to-cradle' approach."Juan Sartori, Founder and Chairman of Union Group remarked: "This is not just a strategic alignment of businesses, it's the creation of a new kind of company for the 21st century. By combining science, scale, and sustainability, Moolec is positioned to lead a global transformation in how we produce food, materials, and energy. I'm proud to support this vision and the exceptional teams bringing it to life."Following the closing of the Business Combination, Moolec will become uniquely positioned in the agricultural value-chain, with a powerful and validated technology discovery and development engine that can address in a cost-competitive way multiple upstream and downstream needs. Moolec's new value proposition will be centered around modifying or improving seeds and microbes to positively impact the way we utilize land and water resources, while preserving and/or improving human health.Alejandro Antalich, Chairman of Synbio Powerlabs® added: "This combination marks a defining moment for the bioeconomy. By integrating next-gen ingredients, biological ag solutions, and deep-tech manufacturing capabilities under one roof, we are building a company with unmatched scientific depth and commercial reach. Together, we aim to accelerate the shift toward a more sustainable and resilient food system, one that works in harmony with nature, rather than against it."As stated in their most recent annual reports, the companies and brands, which will be controlled or co-controlled by Moolec at the closing of the Business Combination, manage a portfolio of more than 800 patents (or patent applications) and over 550 product registrations, which translates into more than half a billion dollars of goods and services sold in their last fiscal year, to customers in more than 50 different countries.José López Lecube, CFO and Director of Moolec commented: "This transformative transaction marks a new stage for Moolec, positioning the company for growth within a broader organization that facilitates synergies on multiple levels. Becoming part of a larger organization will enable cost efficiencies and significant revenue increase as well as product portfolio diversification. It will also enlarge our investor base, providing the company with new stakeholders who support Moolec's new and more diversified business."Finally, as reported Mr. Gastón Paladini will step down as Chief Executive Officer (CEO), Director and Chairman of the Board, effective immediately following Moolec's Extraordinary General Meeting ("EGM") to be held on April 22, 2025.Key highlights:Ingredient Innovation: Moolec will continue to develop its flagship molecular farming products such as Piggy Sooy™ and GLASO™, while integrating Mycofood™ under the Eternal® brand from Nutrecon.Biological Ag Expansion: Through Bioceres Group, Moolec will now offer upstream technologies for regenerative agriculture, including biological inputs and climate-resilient seeds like Rizobacter®, ProFarm®, and the HB4® trait.Advanced R&D and Services: Leveraging expanded infrastructure, Moolec will offer R&D, CDMO, and regulatory services under the Agrality® and Synbio Powerlabs® brands, which are controlled or co-controlled by Bioceres Group and Nutrecon, respectively.Emerging Tech & Equipment: The Company will also expand its reach into emerging technologies for grain and biomass transformation, especially in the biomaterials space, as well as new concepts on farm equipment, integrating material science, electric mobility, and autonomy. These emerging opportunities are being pursued by Gentle Tech and Bioceres Group subsidiaries.Operational Synergies: The Business Combination is expected to result in significant cost synergies and an integrated management structure, which will be presented at or prior to closing of the Business Combination.Timing and ApprovalsThe Business Combination was unanimously approved by the Board of Directors of all the entities participating in the deal. It is expected to close during the second quarter of 2025 or thereafter, and it is subject to finalizing Moolec's reverse stock split process and re-domicile to the Cayman Islands among other customary closing conditions and regulatory approvals. This includes the approval by Moolec's shareholders at a special meeting of shareholders of proposals relating to the Business Combination. Given that the transaction was originally proposed by about 70% of Moolec's current shareholders, the Company expects strong shareholder support for the Business Combination approval.The Business Combination will be consummated through an equity exchange. Bioceres Group's shareholders will surrender their share ownership in Bioceres Group and will receive in exchange up to 80,590,280 shares of Moolec. The shareholders of 100% of Nutrecon and 50% of Gentle Tech will surrender their ownership in these two entities and will receive in exchange 6,475,000 shares of Moolec and 5,000,000 warrants of Moolec at a strike price of $2.00 per warrant, subject to adjustment based on the results of the reverse stock split process.The intrinsic value of the exchange ratio and the $2 strike price of warrants represent both a compelling premium to Moolec's current stock price, and a unique opportunity to assemble one of the most formidable public companies in the agricultural industry.Description of Contributed Entities and AssetsThe Contributed Entities consist of Bioceres Group and its subsidiaries, Nutrecon and its subsidiaries and Gentle Tech and its subsidiaries.Bioceres GroupBioceres Crop Solutions Corp. (NASDAQ: BIOX)Fully integrated provider of crop productivity solutions, including patented technologies for seeds and microbial agricultural inputs, as well as next generation crop nutrition and protection solutions. The company developed HB4® technology, which confers tolerance to climate changes in soybeans and wheat by allowing these crops to tolerate drought and soil salinity conditions. It also owns and licenses more than 570 products with approximately 750 patents and patent applications in the United States, Canada, Brazil, Argentina and other countries.Bioceres Tech Services (Agrality® & Inmet)Agrality® is a global agricultural services provider catering to agro-industrial companies worldwide. Their comprehensive service offerings encompass seed manufacturing and R&D, field-testing, and regulatory capabilities, ensuring their clients receive end-to-end solutions. Agrality's key assets include advanced seed production facilities, enabling high-quality seed development and production.Inmet specializes in the bio-transformation of agro-industrial residues, offering sustainable solutions for waste management in the agricultural sector. They utilize innovative technologies to convert agricultural waste into valuable products. Additionally, Inmet is involved in the production and assessment of bioplastics, contributing to the development of eco-friendly alternatives to conventional plastics.Nutrecon (Synbio Powerlabs®)Headquartered in Helsinki, Finland, Synbio Powerlabs® is an innovative early-stage biotechnology company specialized in research, development, and production of sustainable fungi-derived ingredients. With state-of-the-art laboratories and a pilot-to-industrial scale precision fermentation facility, the company operates uniquely as both a Research and Technology Organization ("RTO") and a Contract Development and Manufacturing Organization ("CDMO"). This dual role enables Synbio Powerlabs® to seamlessly bridge the gap between cutting-edge biotechnology research and real-world industrial applications, accelerating the commercialization of novel bio-based products. Its flagship product line, marketed under the Eternal® brand, features a diverse portfolio of high-quality, sustainable ingredients derived from fungi, serving multiple industries and applications.Gentle Tech (G-FAS & Gentle Farming)A frontier tech company developing sustainable, autonomous agricultural equipment. Focused on reducing environmental impact through innovations in materials science, information technologies, and alternative energy to maximize efficiency and minimize the carbon footprint. The business model includes G-FAS (selling ultra-light weight harvesting heads directly to farmers) and Gentle Farming (developing machinery for autonomy and intelligent management).Forward Looking StatementsThis press release contains "forward-looking statements." Forward-looking statements may be identified by the use of words such as "forecast," "intend," "seek," "target," "anticipate," "believe," "expect," "estimate," "plan," "outlook," and "project" and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Such forward-looking statements with respect to performance, prospects, revenues, and other aspects of the business of Moolec are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Although we believe that we have a reasonable basis for each forward-looking statement contained in this press release, we caution you that these statements are based on a combination of facts and factors, about which we cannot be certain. We cannot assure you that the forward-looking statements in this press release will prove accurate. These forward-looking statements are subject to a number of significant risks and uncertainties that could cause actual results to differ materially from expected results, including, among others, changes in applicable laws or regulations, the possibility that Moolec may be adversely affected by economic, business and/or other competitive factors, costs related to the scaling up of Moolec's business and other risks and uncertainties, including those included under the header "Risk Factors" in Moolec's Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission ("SEC"), as well as Moolec's other filings with the SEC. Should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. Accordingly, you should not put undue reliance on these statements.Contact InformationPress & Media: comms@moolecscience.comInvestor Relations: ir@moolecscience.comSOURCE: Moolec Science SARelated Documents:Moolec Science Enters into Transformational Transaction Expanding Across Multiple Technology Platforms.pdf Copyright 2025 ACN Newswire via SeaPRwire.com.

22 4 月, 2025

Saudi CFO Summit 2025: Navigating Digital Change & Business Growth

Saudi Arabia, Apr 21, 2025 - (ACN Newswire via SeaPRwire.com) - CFOs in the digital era do more than just run the financial operations of the organization: They now also sit atop the organization where they lead the charge toward financial digitization. CFOs have an eminent role to play here in driving process standardization and automation efforts and ensuring that their organizations on board with technologies such as RPA, AI, and machine learning. With the continuous advancement of these technologies, however, the CFO is left wrestling with the issue of assessing critically which of these instruments would add real value and which ones are simply trends. A CFO should confirm that he or she does not show any biases and will also use sound judgment in arriving at decisions with respect to new technologies rather than blindly following the latest fad. Achieving this balance while navigating a dynamic environment is the major challenge of today's CFO: the technocrat should balance the adoption of technology with corporate foresight, with the understanding that innovation should facilitate long-term financial goals and operational efficiency.In the Middle East, there’s a growing misunderstanding about the roles of Certified Public Accountants (CPAs) and Chief Financial Officers (CFOs), which is creating challenges for effective financial leadership and overall business performance. While CPAs are focused on compliance, audits, and ensuring financial accuracy, CFOs are responsible for steering the company’s overall financial health.The 25th Edition CFO Leadership Summit, taking place on April 23rd, 2025, at the Radisson Blu Minhal in Saudi Arabia, will help address this by bringing together over 200 finance leaders to dive into the latest trends and disruptions in the industry. Through engaging presentations, panel discussions, and real-world case studies, the event will offer valuable insights to help finance professionals sharpen their skills and stay ahead in a rapidly changing market. The sessions will cover everything from making strategic decisions and managing investments to effectively communicating with stakeholders and navigating risks around cash flow, capital allocation, and regulatory compliance. Who will Speak?Heni Jallouli, Group Chief Financial Officer, Jahez International Company.Ozgur Oncu, Group Chief Financial Officer, Petromin Corporation.Mohamed Helal, Group Chief Financial Officer, Al Watania For Industries.Amit Kauntia, Group Chief Financial Officer, Abdul Mohsen Al Tamimi Group. Sarfaraz Ahmed,Group Chief Financial Officer,Saudi Cable.Arif Idrees,Group Chief Financial Officer,Tahweel Holding.Hussam Abdullah,BukhariGroup Chief Financial Officer,Takamol Holding.Rami Abuelsamen,Regional Chief Financial Officer,Almana Group of Hospitals. The event will cover topics like:CFO's Playbook: Navigating Strategic Communication.Investing in Tomorrow: CFO Strategies for Sustainable Growth.Future-Proofing Finance: Advanced Scenario Planning for Complex Business Environments.From Numbers to Narratives: Debunking Common Misconceptions.Driving Business Growth: Advancing with AI and Automation.Adaptability in the Face of Change:The Evolving Role of the CFO.For more information on the 25th Edition CFO Leadership Summit : LinkAbout ExitoExito, which means success in Spanish, embodies our commitment to the success of our customers. Each year, we host over 240 virtual and in-person conferences globally, bringing together audiences with world-class thought leaders and C-level executives across industries. Our meticulously crafted agendas, based on extensive research and valuable industry insights, facilitate business, knowledge transfer, deal flow, and impactful messaging for brands.For Media Enquiries, contact:Kasturi Nayak (Sr.) Marketing ExecutiveKasturi.nayak@exito-e.comEnquiry@exito-e.com Copyright 2025 ACN Newswire via SeaPRwire.com.

21 4 月, 2025

A Strategic Event for HR Leaders and Experts to Drive Transformation in the Saudi Workforce

Saudi Arabia, Apr 21, 2025 - (ACN Newswire via SeaPRwire.com) - Saudi Arabia, as a developing country, has achieved tremendous progress in changing its human resources development (HRD) sector, but it still faces hurdles in aligning its workforce with the needs of rapid economic growth. Despite recent social and economic reforms, Saudi labour markets continue to struggle to fulfil the country's changing economic needs. Human Resource Development is crucial to this change, serving as an indicator of the country's social, cultural, and economic growth. The National Human Resource Development (NHRD) framework empowers HR professionals to go beyond company talent development and address larger national challenges. This framework serves to highlight labour market concerns while also ensuring that HRD policies are adapted to the needs of the future workforce.The Human Capability Development Program (HCDP), started in 2021 as part of Saudi Arabia's Vision 2030, intends to empower citizens while also increasing global competitiveness. The HCDP is intended to produce a competitive national workforce by emphasizing value promotion, future skill development, and knowledge enhancement. To do this, continual analysis of NHRD policies is required to align labour demands and supply, resulting in successful workforce planning for long-term national growth. This strategic strategy is critical for providing the Saudi workforce with the skills needed to face future problems.Overview of the event:The 4th Edition of the HR World Summit, themed "Unlocking the Future of Human Potential," is a premier, invitation-only event that brings together over 200 HR leaders and experts. Set to take place on April 24, 2025, at the Radisson Blu Minhal, this summit offers an exclusive platform for in-depth discussions on the challenges and opportunities in human resources. With a focus on advancing skill development, promoting innovation, and implementing effective strategies to enhance organizational competitiveness, attendees will gain valuable insights and tools to drive transformation. This gathering of CHROs, VPs of HR, talent management leaders, and HR professionals will foster impactful networking and provide actionable solutions to elevate organizational performance in today’s rapidly evolving landscape.Who will Speak?Abdullah Zabin AlOtaibi, Vice President of Upstream HR at Aramco.Ahmed Omar Baaboud, Chief Shared Services Officer at Real Estate Registry.Hessah Fahad Moammar, Vice President of People & Culture at ACWA Power.Ratibah Aljawini, Executive Director of Human Resources for the Human Capability Development Program.The event will cover topics like:Reimagining HR for a Digital Age: Navigating the Saudi Arabian LandscapeAddressing Quiet Quitting: Retaining Top Talent in a Competitive Job MarketAI in HR: A Double-Edged Sword? Balancing Benefits and RisksBreaking Down Barriers: A Conversation on DEI and Workplace TransformationToxic Workplace: Breaking the Cycle and Building a Healthy CultureThe Future of Work: Navigating Uncertainty and Embracing OpportunitiesFor more information on the 4th Edition HR World Summit: LinkAbout ExitoExito, which means success in Spanish, embodies our commitment to the success of our customers. Each year, we host over 240 virtual and in-person conferences globally, bringing together audiences with world-class thought leaders and C-level executives across industries. Our meticulously crafted agendas, based on extensive research and valuable industry insights, facilitate business, knowledge transfer, deal flow, and impactful messaging for brands.For Media Enquiries, contact:Kasturi Nayak (Sr.) Marketing Executive)Kasturi.nayak@exito-e.com Enquiry@exito-e.com  Copyright 2025 ACN Newswire via SeaPRwire.com.

21 4 月, 2025

inter airport Southeast Asia 2025 sets a new benchmark for attendance, marking its 8th edition in Singapore with record-breaking participation

Trade attendees gathered in anticipation for the opening day of IASEA 2025.SINGAPORE, Apr 21, 2025 - (ACN Newswire via SeaPRwire.com) - The 8th edition of inter airport Southeast Asia (IASEA) was held in Singapore from 25-27 March 2025. Spanning across 6,259 sqm of exhibition space, the airport exhibition and conference brought together 3,621 industry trade professionals from 53 countries and regions, and featured 134 exhibiting companies including pavilions representing Germany, Italy, Japan and Singapore.The event saw a 43% increase in exhibitor size and a 15.6% rise in attendee numbers, underscoring the rising significance of IASEA as a platform for productive discussions. The event's achievement is also attributed to the increasing demands of operators and the rapid development and expansion of airports in Asia.The landmark event in Asia featuring the latest innovations and solutions for airportsIASEA serves as the dedicated event for airports, airlines, aviation authorities, ground handlers and related business executives in Asia to learn about and experience the latest products, services and technologies, for the future development of Asia’s airports.One of the highlights of this year’s edition was the presence of a delegation of leaders from major international airports in Vietnam, including Long Thanh International Airport—one of the world's most expensive greenfield airport projects—Noi Bai Airport, Danang Airport, Cat Bi Airport, Phu Quoc Airport, and Cam Ranh International Terminal.One of Airports Corporation of Vietnam’s (ACV) primary objectives in the coming years is the successful completion and operation of Long Thanh International Airport. Under the direction of the Prime Minister of Vietnam, the presence of ACV’s delegation at IASEA 2025 was to seek high-quality solutions and potential partners for this airport. Mr. Nguyen Cao Cuong, Deputy General Director, Airports Corporation of Vietnam (ACV), shared during his opening remarks, “Vietnam, as one of the fastest-growing aviation markets in the world, is actively developing key airport infrastructure projects to meet the increasing demand for air transport. This event is not only an opportunity to explore the latest advancements in aviation technology but also serves as a platform for collaboration and exchange, fostering stronger partnerships to enhance airport infrastructure across Southeast Asia."Attendees explored innovative airport solutions on the IASEA 2025 exhibition floor.First-time exhibitor Thales participated to expand business opportunities with regional aviation players and introduce solutions such as its latest Fly-to-Gate biometrics solution that enables a touchless, fast, and easy passenger journey from check-in to boarding. Thales commented, “Air traffic has fully recovered since the pandemic years. The increase of major projects and the prioritisation of data (data management, data sharing, data security) from airport decision-makers have grown vastly within the industry. At Thales, we recognise that data will improve efficiency in airport operations – namely terminal operations, aircraft turnaround, passenger flow – beyond what hardware can achieve. However, these advancements also come with challenges, including cybersecurity and leveraging data while keeping airport operations human-centric. Our participation at the conference and exhibition of IASEA 2025 allowed us to connect and engage in discussions with several airport and aviation representatives. We were also able to share Thales’ expertise in airport operations and security, cybersecurity resilience, and biometric solutions, all for a seamless passenger experience.”Smiths Detection, a global leader in threat detection and security screening technologies, introduced the SDX 10060 XDi to the Asia market – a leading-edge X-ray scanner that offers highly accurate material discrimination and substance identification based on an object’s molecular structure. “We are glad to be back at IASEA, a key platform for us to showcase our latest solutions and connect with both customers and prospects because the show attracts aviation leaders from across the region,” said Desmond Lian, Senior Solutions Consultant, Smiths Detection (Asia Pacific) Pte. Ltd. “It was especially meaningful to reconnect with major airports such as Narita International Airport Corporation, as we discuss each other’s long-term plans and areas of collaboration. Such conversations make me hopeful for stronger integration of AI and security systems across the air and land side of the aviation industry. I hope to see the development of an architecture platform where different industry players can share and communicate data, and tackle cybersecurity issues as an ecosystem.”Additionally, Mallaghan, one of the fastest-growing airport Ground Support Equipment (GSE) manufacturers (headquartered in Ireland and with a worldwide presence), returned to the 8th edition of IASEA 2025. Niall Mallaghan, Director at Mallaghan, shared, “IASEA has always been one of our go-to exhibitions for the Asia Pacific region because of the opportunities to meet leading suppliers and our customers such as dnata and SATS. While the industry traditionally relied on diesel-powered GSE, Mallaghan, together other industry leaders, have recognised the impact of electrifying ground handling equipment as an effective route towards greener aviation. At Mallaghan, we strive to enable airports to reach their sustainability goals by working closely with the ground handlers.”Conversations that focused on resilient, data-driven airportsIn line with this year’s theme, “Airport Operations for Tomorrow”, the conference and exhibition floor saw timely conversations on the use of technology – more specifically, data and Artificial Intelligence (AI) – to drive resilient airports of tomorrow. “With the ever-increasing complexities of running an airport, the chances of something going awry also rise significantly.  Thus, keeping airport operations resilient is paramount,” said David Jea, GM, Safety, Security & Business Continuity, Airport Authority Hong Kong. “As a conference speaker of this year’s IASEA, I’m thankful for the opportunity to engage with peers on aviation security, and the exposure to the full range of innovations for airport operations, with my greatest harvest being the appreciation of technology for optimised operations. The airports of tomorrow necessitate industry players to use AI and other technologies effectively, ensuring the solutions adopted are advanced and secure, workers are trained with more proficient skill sets, and the industry continues to attract professionals.”Industry experts at one of the IASEA 2025 terminal operations panels ‘Future-Proofing Airport Security: Balancing Safety, Technology & Passenger Experience’As of 2024, Asia Pacific holds over 40% of the global aircraft orders, signifying a strong focus on fleet investment and renewal for the region. Ensuring airports keep up with this projected regional growth, the panel titled ‘Using Data Analytics to Optimise Airport Operations’ dived into the challenges and opportunities of harnessing data analytics to drive innovation and ensure sustainable growth in airport operations. Industry leaders acknowledged that airports typically generate a wealth of live data that can help to enhance the passenger experience. However, a core challenge is in utilising this data – the industry is looking to integrate all data on a single system for real-time processing, while ensuring security measures are in place in the face of cyber threats. Separately, on the ground handling side, the conference panel ‘Boosting Operational Resilience: Preparing for the Unexpected’ gave a comprehensive overview of how ground handling teams can build robust operations that withstand unforeseen challenges of equipment failures, staffing shortages, and extreme weather. Panellists emphasised the role of ground handlers in adapting to unique equipment and processes deployed across individual airports. Disruptions can come in many forms. Hence, it is imperative for the ground handlers to work closely with the airports (with diverse teams across different airports) to analyse big data, address the disruption, and re-instil confidence in passengers.inter airport SEA will return for its 9th edition in 2027, from 23-25 March. For more exhibition and conference highlights, please visit the event website, LinkedIn, or Facebook pages. About inter airport Southeast Asiainter airport Southeast Asia influences and accelerates the transformation of the airport industry in Asia by crafting a unique, 3-day airport trade show for the region.Every odd year, buyers and decision makers from the airports, airlines, ground handlers and the entire Airport community in Asia attend inter airport Southeast Asia to source and experience from the most diverse selection of innovations, technology and equipment for airport terminals and ramp operations.Whatever your strategy or needs - this is the place to be for business, friendship and new trends.23-25 March 2027Marina Bay Sands, Singaporewww.interairport-southeastasia.comAbout RX  RX is a global leader in events and exhibitions, leveraging industry expertise, data, and technology to build businesses for individuals, communities, and organisations. With a presence in 25 countries across 42 industry sectors, RX hosts approximately 350 events annually. RX is committed to creating an inclusive work environment for all our people.  RX empowers businesses to thrive by leveraging data-driven insights and digital solutions. RX is part of RELX, a global provider of information-based analytics and decision tools for professional and business customers. For more information, visit www.rxglobal.com.About RELXRELX is a global provider of information-based analytics and decision tools for professional and business customers. RELX serves customers in more than 180 countries and has offices in about 40 countries. It employs more than 36,000 people over 40% of whom are in North America. The shares of RELX PLC, the parent company, are traded on the London, Amsterdam and New York stock exchanges using the following ticker symbols: London: REL; Amsterdam: REN; New York: RELX.*Note: Current market capitalisation can be found at http://www.relx.com/investorsMedia contacts (on behalf of RX)Carolyn Kok (carolyn.kok@fifthring.com)Chloe Lim (chloe.lim@fifthring.com) Copyright 2025 ACN Newswire via SeaPRwire.com.

21 4 月, 2025

PerfectSwell(R) Zion To Start Construction

SOLANA BEACH, CA, Apr 17, 2025 - (ACN Newswire via SeaPRwire.com) - American Wave Machines, the global leader in world-class surf pool destinations, announces a new project, PerfectSwell® Zion, a mixed-use development in Washington, Utah, the outdoor activity hub adjacent to Zion National Park. AWM is partnering with Desert Lakes LLC on the project. The commercial surf park anchors a luxury residential community called Zion Shores offering waterfront single family homes and beachfront townhouses. PerfectSwell® Zion will be open to the public with Zion Shores residents enjoying unique perks and surf priority. PerfectSwell® Zion opens in Q1 2027.Capping four years of in-house R&D, the project will feature Generation 6 PerfectSwell® surf technology bringing bigger, better waves, improved efficiency, cutting-edge sustainability features, and AWM's most innovative wave package yet. Gen 6 features optimization diagnostics utilizing historic and real time data, innovative health monitoring, maintenance schedules, and a thermal design system for air and water temperature management. Further improvements in pneumatics have resulted in measurable increases in wave generating efficiency. In terms of design, natural and permanent elements will be utilized for energy dissipation in the water minimizing the use of fabricated materials. For the surf and aquatics recreation, the project will upcycle brackish water - unfit for drinking or farming - conserving fresh water and reducing waste."We have just about every outdoor activity you can think of in this high desert playground except surfing. We're stoked to partner with AWM to change that. The team behind PerfectSwell® is the real deal," said Cody Larkin, CEO of Desert Surf, LLC. "AWM makes the type of waves they want to surf with a mandate of continuing innovation. We're ready to go.""Gen 6 PerfectSwell® is next level, and I can't think of a better location for the debut or a better partner in the US. Desert Lakes brings a wealth of expertise in civil construction and community infrastructure building, essential for a successful project," said Bruce McFarland, President of AWM. "We're thrilled to work with Cody and his team to expand our global network of deeply connected surf communities to Utah and beyond."About American Wave MachinesAmerican Wave Machines, Inc.is the inventor and developer of PerfectSwell® Surf Technology. AWM's technology powers world class surf facilities and destinations backed by proven financials, extensive data capture, and stoked surfers. PerfectSwell® is the only sequence based, pneumatic surf technology on the market. Protected by over 50 patents worldwide, PerfectSwell® Split Peaks, Peeling Waves, Air Sections, and Wedge Barrels are all covered by AWM's robust patent portfolio.About Desert Lakes LLCDesert Lakes LLC is a dynamic partnership between Immaculate Homes and Salt Lake Excavating, formed in 2019 to develop the renowned Southern Shores community in Hurricane Utah. This unique waterfront development features three man-made lakes designed for boating, surfing, and a variety of recreational activities, all surrounded by premium residential properties. Cody Larkin brings extensive expertise in civil construction and lake development, while Jason and Brittany Christensen of Immaculate Homes lead the charge on vertical construction, combining their strengths to create one-of-a-kind living experiences.Contact:Jenna Timinskyinfo@americanwavemachines.comSOURCE: American Wave Machines, Inc. Copyright 2025 ACN Newswire via SeaPRwire.com.

18 4 月, 2025

OMP Positioned Highest for Ability to Execute in the 2025 Gartner(R) Magic Quadrant(TM) for Supply Chain Planning Solutions

ANTWERPEN, BELGIUM, Apr 17, 2025 - (ACN Newswire via SeaPRwire.com) - OMP, a global leader in supply chain planning solutions, has been named a Leader in the Gartner Magic Quadrant for the 10th consecutive time. Positioned highest for 'Ability to Execute,' OMP believes this recognition underscores its consistent delivery of innovative solutions and measurable business results to global supply chains.A proven platform for the most complex planning needsOMP attributes its continued advancement to the strength of Unison Planning™, a proven platform for all supply chain planning needs - from strategic to operational, and from demand to supply. As an open, cloud-native, and AI-driven platform, Unison Planning is designed to meet the evolving demand of dynamic global supply chains. It empowers businesses to make smarter, faster decisions and collaborate more effectively across complex networks."Today's supply chain leaders must make decisions at the speed of business to stay competitive. It's the only way to deal with tariffs, geopolitical shifts, and disruptions, while also harnessing new opportunities," says Philip Vervloesem, Chief Commercial & Markets Officer at OMP.Smarter, faster planning with AI at the coreOMP's decision-centric planning approach leverages AI to generate realistic scenarios, helping business leaders keep their supply chain agile and resilient."Unison Planning enables businesses to make data-driven decisions more efficiently," says Tom Wouters, Chief Product Officer at OMP. "Our AI-powered approach proactively optimizes supply chain operations, while OMP Companion, our generative AI assistant, drives user adoption and collaboration to unlock the platform's full value."Co-innovation in actionOMP's innovation strategy is rooted in close collaboration with its customers, ensuring that the platform evolves in direct response to the real-world challenges faced by global supply chains."We're excited about our co-innovation initiatives, which deliver real results for our long-term customers and partners," adds Philip Vervloesem. "We believe this year's position validates our approach of solving our customers' toughest challenges together and driving growth across our ecosystem."Customer success through strategic long-term partnershipsTrusted by Fortune 500 companies, such as AstraZeneca, Dow, Johnson & Johnson, and Nestlé, OMP continues to deliver scalable results across industries through strong partnerships."We're proud of our trusted partnerships with leading global companies within our target industries," says Paul Vanvuchelen, CEO of OMP. "I strongly believe this recognition reflects the value of 40 years of deep supply chain planning expertise, and I thank our dedicated teams, loyal customers, and alliance partners for their continued support."About the Gartner Magic QuadrantThe 2025 Gartner Magic Quadrant for Supply Chain Planning Solutions, released in April 2025, evaluates vendors based on their Ability to Execute and Completeness of Vision, helping business leaders identify the right partners in a complex and fast-evolving market.For more information about OMP's position as a Leader in the Gartner Magic Quadrant and the future of supply chain planning, read the full report here.Contact InformationPhilip VervloesemSenior Vice President OMP USApvervloesem@omp.com+1-770-956-2723SOURCE: OMP Copyright 2025 ACN Newswire via SeaPRwire.com.

18 4 月, 2025

Announcing Zion Shores

Washington, Apr 18, 2025 - (ACN Newswire via SeaPRwire.com) - Alaia Development and Desert Lakes LLC are thrilled to announce ZION SHORES - a world class inland surf destination in Washington, Utah. ZION SHORES will be the centerpiece of the Alaia's Master planned community, formerly known as Stucki Farms. After years of water research, engineering, and collaboration with the city of Washington, we have reached an agreement and are moving forward on a monumental project in the heart of southern Utah. This will truly be unlike any other surf and recreation area in the world.Water is a precious resource, especially in Southern Utah, and ZION SHORES was conceived and designed with the vision of protecting that resource. Our surf lagoons will be filled with non-potable brackish water not suitable for drinking or irrigation from privately owned onsite wells. Brackish water is much too costly to convert into culinary or irrigation quality, but with a little chemistry added, it is entirely safe for recreation. In addition, Alaia worked closely with Washington City to significantly reduce the size of the previously approved lagoons. Without drawing from local drinking or irrigation water supplies, we are turning an otherwise unusable resource into a world-class surf and recreation amenity that will benefit the community.The project will feature 65 short-term rental properties built around two concrete-lined, clear lagoons designed specifically for surfing and other water recreation. Owners and renters of these 65 properties will have priority access to the waves. The public will also have access to through the booking portal. Alaia, the surrounding master planned community, will also include several restaurants, approximately 300,000 sf of commercial space and a community clubhouse overlooking the surf lagoons. ZION SHORES and Alaia will be unlike any other surf and recreation destination in the world with three separate cutting-edge wave technologies producing perfect waves of every shape and size for a fully customized surfing experience:PerfectSwell Zion - A world class surf venue featuring cutting-edge 6th generation PerfectSwell® technology and the most innovative wave package to date. PerfectSwell® is patented, proven and reliable, developed by American Wave Machines in California. Addictingly fun for every skill level, the waves at PerfectSwell® Zion are "Always Peaky".UNIT Zion Dynamic Wave - A groundbreaking 164' wide dynamic wave developed by UNIT Surf Pool that will be the first of its kind in the world. This technology generates multiple moving wave pockets using patent-pending programmable water flow control tech.UNIT Zion Standing Wave - A 60' wide standing wave system by UNIT Surf Pool, which is UNIT's flagship wave and a staple of inland surf technology offering incredible flexibility and adjustability to a unique and controlled experience for all skill levels.From first timers to seasoned surfers, ZION SHORES will be a surf paradise for the whole family. Get ready Utah - the Swell is coming!To learn more about ZION SHORES, visit zionshores.com and alaiaut.comContact:Cody Larkin801-231-9686cody@saltlakeexcavating.comSOURCE: Zion Shores Copyright 2025 ACN Newswire via SeaPRwire.com.

18 4 月, 2025